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Regulation of gene transcription is an important aspect of insulin’s action. However,
the mechanisms involved are poorly understood. Insulin inhibits glucagon gene
transcription and insulin deficiency is associated with hyperglucagonemia that
contributes to hyperglycemia in diabetes mellitus.
  In the present study transient transfection analysis in a glucagon-producing
pancreatic islet cell line was performed, where the activity of an artificial
minienhancer consisting of synergizing Pax6 binding sites (G3A) in front of a
heterologous promoter, as well as Pax6 activity when assessed using a GAL4/viral
E1B system, were inhibited by insulin. This provides evidence that Pax6 can confer
negative regulation by insulin in pancreatic islets.
  Furthermore, Pax6 seems to play a critical  role in the insulin responsiveness of the
glucagon promoter because the overexpression of the Pax6 paired domain as well as
the mutation of the Pax6 binding sites within the glucagon promoter element G1 and
G3 markedly reduced basal activity and insulin responsiveness. The expression of
GAL4-Pax6 and GAL4-VP16 restored basal activity of the doubly mutated promoter,
whereas only GAL4-Pax6 restored also insulin responsiveness.
  When the potential Pax6 coactivator CBP was fused to the GAL4 DNA-binding
domain, the GAL4-CBP activity was inhibited by insulin within the glucagon promoter
context but not in front of the viral E1B promoter. Fusing N-, C-terminal and  middle
parts of CBP with the GAL4 domain only the N- and C-terminal part conferred
transcriptional activity and insulin responsiveness. Further mapping of the C-terminal
of CBP revealed a single region between aminoacids 2040 and 2170 sufficient to
confer the negative regulation by insulin. The activity conferred by this region as well
as by the N-terminal part of CBP was inhibited by the overexpression of the
constitutively active form of PKB, myrPKB.
  The results of present study suggest that the paired domain transcription factor
Pax6 is required for insulin responsiveness of the glucagon promoter. They also
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indicate that the Pax6-interacting coactivator CBP might be involved in this process.
It is finally speculated that within the specific context of the glucagon promoter a
nucleoprotein complex is being induced with Pax6 and CBP as critical components.
Insulin-induced signalling pathways might target this large, glucagon promoter-
specific protein complex rather than any single transcriptional factor and therefore act




  The regulation of gene transcription by insulin is an important facet of this
hormone’s action. Insulin has been shown to stimulate or inhibit the transcription of a
large number of genes (O’Brien and Granner 1996). Based on the hormone response
element paradigm, there has long been speculation that the effects of insulin are
mediated through a common insulin-responsive element (IRE) and binding
transcription factor (Alexander-Bridges et al. 1992, O’Brien and Granner 1991,
O’Brien et al. 1990). IREs have been characterized in a number of genes but, unlike
cAMP, which regulates gene transcription predominantly through one cis-acting
element, the CRE (Meyer and Habener 1993), it became apparent that a single
consensus IRE does not exist (O’Brien and Granner 1996, Chapman et al. 1999).
Likewise, diverse transcription factors have been suggested to mediate the insulin
response, including AFX (Kops et al. 1999), FKHRL1 (Brunet et al. 1999), FKHR
(Durham et al. 1999), GABP (Ouyang et al. 1996), Fra-2/Jun D (Chapman et al.
1999, Streeper et al. 1998), Egr-1 (Barroso and Santisteban 1999), NF-1 (Ortiz et al.
1999), USF (Wang and Sul 1997), IRE-ABP (Alexander-Bridges et al. 1992), and
SRF (Thompson et al. 1994). On the other hand, it has also been suggested that
insulin may act independently of an IRE and target arrays of interacting transcription
factors at the coactivator level (Leathy et al. 1999, Pierreux et al. 1999, Pierreux et al.
1998).
   The genes that are negatively regulated by insulin include the one encoding
glucagon (Philippe 1989).
1.1 Glucagon in diabetes mellitus.
Diabetes mellitus is one of the most prevalent disease in the Western world, affecting
3 to 5% of the population of Europe and Northern America and about 100 million
world-wide (Cohen et al. 1997). Apart from insulin deficiency diabetes is also
characterised by high glucagon levels. The key biological actions of glucagon
converge on regulation of glucose homeostasis: glucagon stimulates glucose
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production by glycogen breakdown and gluconeogenesis in the liver (Unger and Orci
1981, Lefébvre 1995). Secretion of glucagon is inhibited by insulin and glucagon
functions as a counterregulatory hormone, opposing the actions of insulin, and
maintaining the levels of blood glucose. Therefore in insulin-deficient patients with
diabetes, excess glucagon secretion plays an essential role in the metabolic
perturbations associated with diabetes, such as hyperglycaemia (Unger and Orci
1981, Philippe 1989, Lefébvre 1995, Shah et al. 1999). Hence mechanisms of
inhibition by insulin of glucagon secretion and gene transcription present an
important and useful target for medical intervention in treating diabetics with insulin
deficiency.
1.2 The insulin signalling pathway.
The recent years have seen great advance in the understanding of initial steps in
insulin signalling pathway (Fig. 1). Insulin initiates its pleiotropic effects by binding to
its specific, cell surface receptor, the insulin receptor (Kasuga et al. 1982). Insulin
binding leads to the autophosphorylation of the insulin receptor and activation of the
receptor tyrosine kinase (RTK), which in turn leads to the phosphorylation of
endogenous substrates (Kasuga et al.1982). Direct substrate for the insulin RTK are
molecules of insulin receptor substrates (IRS) (Kellerer et al.1999), which are
phosphorylated by the RTK on numerous tyrosine residues. The phospho-tyrosines
of the IRS serve as docking sites for many signalling molecules (Cheatham and Kahn
1995). One of the proteins binding to IRS is PI-3-OH-kinase (PI-3-K). Binding to the
IRS activates PI-3-kinase, which in turn phosphorylates membrane inositol lipids at
the 3’ position of the inositol ring to generate the 3-phosphoinositides: PI(3)P,
PI(3,4)P2 and PI(3,4,5)P3 (Vanhaesebroeck et al.1997). One of the well-established
targets of PI-3-K activation is the Ser/Thr protein kinase B (PKB). PKB is thought to
bind through its pleckstrin homology domain (PH) to the 3-phosphoinositides, which
leads to PKB recruitment to the plasma membrane and also contributes to its
activation (Downward 1998). In response to insulin and growth factors PKB becomes
phosphorylated at two major sites, Thr308 and Ser473 (Alessi et al.1996), which
results in its activation (Alessi et al.1997, Stokoe et al.1997). Two kinases
responsible for this phosphorylation have been recently identified and termed PDK1
and PDK2 (Alessi et al.1997). The first direct in vivo substrate of PKB to be identified
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was GSK3 (Cross et al.1995), which upon phosphorylation by PKB is inactivated,
and this leads to activation of glycogen synthesis, an important feature of insulin
action on the metabolism (Shaw et al.1997). Another target for PKB is the ribosomal
protein S6 kinase (p70S6K) (Burgering and Coffer 1995), and the 6-phosphofructo-2-
kinase (PFK-2) (Deprez et al.1997). Recent reports reveal that PKB is also involved
in protecting cells from apoptosis, and in promoting cell survival by phosphorylating
the pro-apoptotic Bcl-2 family member, BAD (Datta et al.1997).
Fig. 1. Insulin signalling pathway. (See the text for further details).
  Insulin can act also through another, ras/MAP-dependent pathway (Fig. 1). In this
pathway growth factor receptor-bound protein 2 (GRB-2) links IRS to the guanine
nucleotide exchange protein Sos, which activates p21ras (Cheatham and Kanh 1995).
Ser/Thr protein kinase Raf-1 is a direct target of activated p21ras, and  Raf-1 has
been demonstrated to phosphorylate and activate MAP kinase-kinases (MAPKK or
MEK) (Kyriakis 1992), which then activate MAP kinases.
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1.3 Glucagon and pancreatic islet.
Glucagon is a 29-amino acid peptide hormone. It is a member of a structurally related
group of peptides which include secretin (Mutt et al.1970), vasoactive intestinal
peptide (Mutt and Said 1974), gastric inhibitory peptide (Brown 1971), and growth
hormone-releasing hormone (Spiess et al.1982). Glucagon is produced and secreted
by the A cell of the pancreatic islets (Unger and Orci 1981, Orskov et al.1986) and its
secretion is regulated by blood levels of glucose (Gerich et al.1976), and amino acids
(Assan et al.1977) as well as a variety of hormonal stimuli (Samols et al.1983). The
pancreatic islet is a highly specialised endocrine organ with a specific structure.
Insulin-secreting B-cells (60% of the islet) form the core of the islet, whereas A-cells
(25%) form the outer rim. Somatostatin-producing D-cells and pancreatic peptide-
producing PP-cells are dispersed between A and B cells and constitute about 10% of
islet mass (Bonner-Weir et al.1991, Thews et al.1991, Slack 1995). This highly
organised structure is believed to be crucial for properly co-ordinated secretion of
pancreatic hormones and reflects functional interrelations between them. B-cells in
the islet centre produce insulin, which directly acts on the A-cells where it inhibits
glucagon secretion. In this tightly co-ordinated biologic system antagonist hormones
are regulated in autocrine, paracrine, nervous and metabolic way: somatostatin
inhibits insulin and glucagon secretion, glucagon on the other hand stimulates
secretion of insulin and somatostatin (Reichlin 1983).
1.4 Expression of the glucagon gene.
The glucagon gene is mainly expressed in the A-cell of the endocrine pancreas
(Unger and Orci 1981, Habener et al.1991), intestinal L-cells (Drucker 1998), few
neurons in the brain (Drucker and Asa 1988) and at low levels in the thymus
(Throsby et al.1998). The resulting proglucagon peptide is processed differentially in
these tissues (Drucker and Asa 1988, Habener et al.1991, Drucker 1998), giving rise
to glucagon in the pancreatic A cells, glucagon-like peptide 1 (GLP-1), GLP-2, and
oxyntomodulin in the intestinal L-cells, which are implicated in the regulation of
insulin secretion, stimulation of intestinal epithelium proliferation and glucose
absorption in the intestine, respectively (Drucker 1998). In the brain GLP-1 is formed




1.5 The glucagon promoter.
The molecular mechanism of inhibition of glucagon gene transcription by insulin is
poorly understood. It has been demonstrated that in pancreatic islets the level of
glucagon mRNA is negatively regulated by insulin (Philippe 1989) and 350 base pairs
of the 5’-flanking region of the rat glucagon promoter are sufficient to confer the
insulin responsiveness in the glucagon producing islet cell line InR1-G9 (Philippe
1991). It has been also proposed that an enhancer-like element G3 functions as an
IRE of the glucagon gene (Philippe 1991). However, recently a 5’-, 3’-, and internal
deletion analysis and oligonucleotide cassette insertions failed to identify a single
insulin-responsive element in the glucagon gene (Grzeskowiak et al. 2000).
Consequently, it was proposed that insulin responsiveness depends on the presence
of both proximal promoter elements and more distal enhancer-like elements
(Grzeskowiak et al. 2000).
  During the last decade, by deletional, linker-scanning and DNase I footprint
analyses, major cis-regulatory elements in the -350 region of the glucagon promoter
have been identified. It was possible in many instances to characterise also trans-
acting nuclear proteins (Fig. 2) (Philippe et al.1988, Lee et al.1992, Knepel et
al.2000). Within these elements two groups can be distinguished: proximal promoter
elements encompassing G1 and G4, and so called more distal enhancer-like
elements: G2, G3 and CRE. The proximal promoter region (base pairs -136 to +58)
confers on its own low transriptional activity, however is required to mediate
activation of transcription by enhancer elements G2 and G3, and may play a role in
restricting transcription to cell lines with A-cell phenotype (Philippe et al. 1988, Morel
et al. 1995). The proximal promoter element  G1 (base pairs –97 to –65) contains
AT-rich motifs (Morel et al.1995), which have been demonstrated to bind
homeodomain-containing transcription factors. These include LIM homeodomain
protein Isl-1 (Wang and Sul 1995), the caudal-related homeodomain protein cdx-2/3
(James et al.1994, Jin and Drucker 1996, Laser et al.1996) and the POU domain
transcription factor brain-4 (Hussain et al.1997). In addition to Isl-1, cdx-2/3 and
brain-4, also the transcription factor Pax6 binds to the G1 element (Fig.2 and 3).
Pax6 contains two DNA-binding domains: a homeodomain and a paired domain.
Pax6 binding to G1 was shown to regulate positively transcription of the glucagon
gene in a synergistic way with cdx-2/3 (Andersen et al.1999, Ritz-Laser et al.1999).
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Next to the G1 element is a region called G4 (-150 to -91 bp) containing sites binding
Pdx1, the basic region helix-loop-helix proteins E2A (E12/E47/E2/5) and Beta2
(Neuro D) (Kruse et al.1993). Further upstream are located two enhancer like
elements: G2 (-192 to -174 bp) and G3 (-264 to -238 bp), which display islet-specific
enhancer-like properties inasmuch as they enhance expression in some
phenotypically distinct pancreatic islet cell lines but not in several nonislet cell lines.
G2-binding transcriptional factors include Hepatocyte Nuclear Factor (HNF) -3α, -3β,
-3γ, which belong to HNF-3/forkhead  family of transcription factors (Kaufmann and
Knöchel 1996) and also Ets-like domain-containing protein (Ets) and NFATp
(Janknecht 1993, Rao 1994, Fürstenau et al.1997, Fürstenau et al.1999). The third
enhancer-like element, octameric CRE, resides between bases –291 to –298 and
confers activation of glucagon gene transcription in response to a rise in the
intracellular cAMP levels (Knepel et al.1990a) and by protein kinase A activation
(Knepel et al.1990a, Miller et al.1993). The CRE-binding protein CREB belongs to
the leucine zipper family of transcription factors. It has been shown to confer calcium
and cAMP-dependent activation of the glucagon gene transcription (Meyer and
Habener 1993). The G3 element (-264 to -238 bp) comprises two domains: A and B
which bind different nuclear proteins (Knepel et al.1990b). Transcription factors which
bind to G3B domain were characterised as a heterodimer containing homeodomain
proteins: prep1/pbx (Herzig et al. 2000). G3A domain contains a core sequence
TTTYACRCCTSA which is also found in upstream element (UE) of the rat
somatostatin gene, the enhancer 1 element (E1) of the rat insulin I gene and G1
element of rat glucagon gene (Knepel et al.1991).
Fig. 2. –350 bp region of the rat glucagon gene with indicated regulatory DNA
elements and their transcription factors. See the text below for further details.
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This sequence confers transcriptional activity in cell lines of A-cell phenotype and
therefore was termed pancreatic islet cell-specific enhancer sequence, PISCES
(Knepel et al.1991). Recently the paired box-containing transcription factor Pax6 has
been identified as a G3A-binding protein (Sander et al.1997).
1.6 Pax6.
Pax6 is expressed in the central nervous system and the endocrine pancreas during
development and in adult (Strachan and Read 1994), and has been shown to be
crucial for development of these tissues (Sander et al.1997, Mansouri et al.1996).
Pancreata of Pax6 homozygous mutant mice lack glucagon-producing cells,
suggesting that Pax6 is essential for the differentiation of the A-cell (St-Onge et
al.1997).
  The Pax6 gene is expressed in at least two isoforms, only one of which binds the
PISCES motif (Beimesche et al.1999). An alternatively spliced exon 5a results in the
insertion of 14-amino acid peptide in the N-terminal part of the Pax6 paired domain
(Fig. 3). The Pax6 paired domain binds PISCES very well, whereas the extended
variant (Pax6-5a) does not (Beimesche et al. 1999).
Fig. 3. Pax6 cDNA. Indicated are main functional domains (enlarged) and exon structure
from human. UTR - untranslated region, TAD - transactivation domain. An arrow indicates
the alternatively spliced exon 5a.
Recently it has been shown that the C-terminal transactivation domain of Pax6 can
bind to the coactivator p300/CBP (Tang et al.1998, Hussain and Habener 1999),




1.7 The aim of the study.
The aim of the present work was to study the involvement of Pax6 in the regulation of
glucagon gene transcription by insulin. This was approached mainly by performing
transient transfection assays using glucagon-reporter fusion genes and the glucagon-
producing pancreatic islet cell line InR1-G9. The GAL4/E1B system was applied as
well.
Materials  and  methods
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2. MATERIALS AND METHODS
2.1  Chemicals
Braun, Melsungen



























(α-32P)-dCTP (activity 3000 Ci/mmol) (ICN Biomedicals GmbH, Eschwege)
(γ-32P)-dATP (activity > 6000 Ci/mmol) (NEN Life Science Products, Köln)
2.3 Antibiotics and protease inhibitors
Ampicillin          (Boehringer, Mannheim)
Penicillin-Streptomycin solution (Boehringer, Mannheim)
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 2.4 Enzymes and kits









Gene Amp® Thermostable rTth
Reverse-Transcriptase RNA PCR Kit
High PureTM PCR Purification Kit
Mermaid Kit
Original TA Cloning® Kit
OlAquickTM Gel Extraction Kit
Thermo Sequenase Fluorescent












(Bio 101 Inc., USA)
(lnvitrogen, NV Leek, Nederlands)
(Qiagen, Hilden)
Amersham (Braunschweig)
2.5  Bacterial culture materials
Select-Agar  (GIBCO-BRL , Karlsruhe), Select-Peptone (GIBCO-BRL , Karlsruhe),
Select-Yeast Extract (GIBCO-BRL , Karlsruhe), Petri dishes (10 cm) (Greiner,
Frickenhausen).
 2.6 Eukayriotic cell culture materials
DMEM and RPMI 1640 media, and FCS (Gibco-BRL, Karlsruhe).
Falcon dishes (Becton, Dickson, UK).
2.7 Filters and separation columns
Nitrocellulose membranes (Hybond-ECL) (Amersham, USA)
“Poly-Prep Chromatography Columns” (Bio-Rad, Munich)
Materials  and  methods
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2.8 Buffers and media
Routinely used buffers and media were prepared according to “Molecular Cloning”
laboratory manual (Sambrook et al. 1989) using bidestilated, deionised water.
Buffers
LB Medium
Select Peptone 1% (w/v)
Select Yeast Extract 0.5% (w/v)
NaCl 170  mM
For the preparation of agar plates, agar (1.5% w/v) was added to LB medium, and if
appropriate ampicillin (50 µg/ml), or chloramphenicol (34 µg/ml) added. The medium was
autoclaved to sterilise.
10 x MOPS
MOPS 200  mM
NaAc 50  mM
EDTA, pH 7.0 10  mM
1 x PBS
NaCl 140  mM
KCl 2.5  mM
Na2HPO4 8.1  mM
KH2PO4 1.5  mM
pH adjusted to 7.4
RNase A solution
RNase A 0.1 mg/ml
Tris, pH 8.0 5  mM
6 x Stop mix
Glycerine 30% (v/v)
Bromophenol Blue 0.25% (w/v)
Xylene Cyanol FF 0.25% (w/v)
Materials  and  methods
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5 x TBE
Tris, pH 8.0 450  mM
Boric Acid 450  mM
EDTA, pH 8.0 10  mM
TE
Tris, pH 8.0 10  mM
EDTA, pH 8.0 1  mM
Stock solutions
Ampicillin 50  mg/ml
Chloramphenicol 34  mg/ml
6X Loading buffer
Bromophenol blue 30% w/v
Glycerol 50% v/v
TE buffer ad 100%
Media for eukaryiotic cells culture
DMEM medium (1 L): DMEM powder 13g, NaHCO3 3.7g, volume adjusted to 1 L with
distilled water and  filter sterilised.
RPMI medium (1 L): RPMI 1640 medium powder, NaHCO3  2g, volume adjusted to 1
L with distilled water and  filter sterilised.
Medium for InR1G9 cell line
RPMI medium ad 500  ml
FCS 50  ml
Penicillin-Streptomycin Solution 5  ml
Medium for HepG2 cell line
DMEM medium ad 500  ml
FCS 50  ml
Penicillin-Streptomycin solution 5  ml
Materials  and  methods
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Medium for JEG cell line
DMEM medium ad 500  ml
FCS 50 ml
Penicillin-Streptomycin Mix 5  ml
2.9 Oligonucleotides
All oligonucleotides are depicted in 5’ to 3’ orientation.
PCR primers
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EMSA oligonucleotide probes
An oligonucleotide with the sequence of the rat glucagon promoter between bases –
290 and –237 containing the G3 element (bold font), with the 5’-end GATC overhang
(italics font) was used as a probe in EMSA: The PISCES element is double
underlined:
   GATCCTGAAGTAGTTTTTCACGCCTGACTGAGATTGAAGGGTGTAGC
The second oligonucleotide used in this work contained the GAL4-binding motif and
the 5’-end GATC overhang (italics font):
   GATCCGGAGTACTGTCCTCCG
2.10 Reporter gene plasmids
All constructs were sequenced by enzymatic cycle sequencing to confirm the identity
and the orientation of the inserts.
  The construct -350(-150/-91)GluLuc, containing an internal deletion from -149 to -
92, was prepared by PCR replacing the deleted bases by single SacI site. Two PCR
products  generated with primer pairs 1/3 and 2/4 (2.8), were digested by XhoI/SacII
and SacII/BglII respectively and ligated into XhoI/BglII site of pXP2. In the constructs
-350(mutG1)GluLuc, -350(mutG3)GluLuc, and -350(mutG1/G3)GluLuc the Pax6-
binding PISCES motifs within G1, G3 or G1 plus G3 were mutated into a GAL4
binding site. The constructs were generated by PCR from -350GluLuc. For -
350(mutG1)GluLuc two PCR fragments were synthetised  with the primer pairs 1/7
and 8/2 (2.9); after digest with XhoI/EcoRI and EcoRI/BglII respectively, the
fragments were ligated into the XhoI/BglII sites of pXP2. For -350(mutG3)GluLuc two
PCR fragments were generated with the primer pairs 1/5 and 6/2 (2.9); after digest
with XhoI/XbaI and XbaI/BglII respectively, the fragments were ligated into the XhoI-
BglII sites of pXP2. Similarly for -350(mutG1/G3)GluLuc three PCR fragments were
generated with the primer pairs 1/5, 6/7, and 8/2 (2.9); after digest with XhoI/XbaI,
XbaI/EcoRI and EcoRI/BglII respectively these fragments were ligated into the
XhoI/BglII sites of pXP2. The plasmid pCMV-GFPtpz was purchased from Canberra-
Packard, Dreieich, Germany.  The plasmid pBP (Bluescript) was purchased from
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Stratagene, Germany. The constructs, which were used in this work and were not
prepared, are  summarised in Tab. 1. The 4xG3A(T81)Luc contains four copies of the
oligonucleotides containing the A domain from the rat G3 element (bp –277 to -261)
were cloned in front of the –81 bp of the minimal thymidine kinase promoter. In case
of the 4xG2(-136)GluLuc construct four copies of the G2 oligonucleotides were
cloned in front of the –136 glucagon promoter region.
Reporter gene construct Reference
pT81Luc Nordeen, 1988
-350GluLuc Schwaninger et al., 1993
-136GluLuc Grzeskowiak et al., 2000
5xGal4(E1B)Luc Krüger et al., 1997
4xG2(T81)Luc Grzeskowiak et al., 2000
4xG3A(T81)Luc Wrege et al., 1995
pXP2 Nordeen, 1988
Tab. 1. Reporter gene constructs, which were used in this work and were not
prepared.
2.11 Expression plasmids
All constructs were sequenced by enzymatic cycle sequencing to confirm the identity,
the orientation or/and frame of the inserts.
An expression vector encoding GAL4-Pax6 fusion protein was prepared as follows:
the BamHI-KpnI fragment of the plasmid Pax-sc-35 (obtained from P. Gruss, MPI
Göttingen, Germany), containing full length Pax6 cDNA, was cloned into the BamHI-
KpnI sites of Gal4-fusion expression vector - pSG424 (Sadowski et al., 1989); the
HindIII-EcoRV fragment of this plasmid, containing the GAL4-Pax6 fusion protein,
was cloned into the HindIII-EcoRV sites of the CMV-driven eukaryotic expression
vector pBAT14 (obtained from M. German, San Francisco, CA). For preparation of an
expression vector encoding the Pax6 paired domain (pPax6-PD) the plasmid
pBAT14m.Pax6 (obtained from M. German, San Francisco, CA) was digested with
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BglII and HindIII, blunt ended by Klenow fill-in reaction, and fragment containing only
paired box (amino acids 1-246) was religated. All constructs were sequenced by
enzymatic cycle sequencing to confirm the identity and the orientation of the
inserts.Plasmid encoding GST-fused full length Pax6, pGST-Pax6(FL), for bacterial
expression was cloned as follows:  PCR product, using as a template Pax-sc-35
(obtained from P. Gruss, Göttingen, Germany) and primer pair
BamHI(up)/MunI(down) (2.9), was digested by BamHI/MunI and ligated  into
BamHI/EcoRI site of pGEX-2T (Amersham-Pharmacia). The expression constructs,
which were used in this work but were not prepared are listed in the Tab. 2.
Expressional construct  Reference
GAL-CBP8 (full length: amino acids 1-2141) Chrivia et al., 1993
GAL4CBP[1-451] Kurokawa et al., 1998
GAL4CBP[1061-1891] Kurokawa et al., 1998
GAL4CBP[1892-2441] Kurokawa et al., 1998






GAL4CBP[1678-2441] ∆2040-2306 --------/ /--------
GAL4CBP[1678-2441] ∆2040-2170 -------/ /--------
GAL4-VP16 Roberts et al., 1994
GAL4-TADwt Mikkola et al. 1999
GAL4-TADm3 Mikkola et al. 1999
myrPKB             Dr. T. Franke, Columbia University, NY
Tab. 2. Expression constructs, which were used in this work and were not prepared.
GAL4-CBP constructs were generated by fusing the GAL4 DNA-binding domain (amino
acids 1-147) to part of CBP (amino acids indicated in the square brackets). Internal deletion
in the last two CBP constructs is indicated in upper case.
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2.12 Bacterial strains
E. coli strain HB101 (ampR) was used for for standard cloning procedures and
plasmid amplification.  E. coli strain BL21(DE3)pLys (ampR, CAR) (Novagen, USA)
was used for bacterial GST-PAX6 expression.  This strain carries pLys plasmid with
IPTG-inducible T-7 lysozymogen gene.  E. coli strain TOP10F’ (ampR, KAR, LacI)
(Invitrogen, NV, Leek) was used for blue/white screening of RT-PCR product cloning.
2.13 Eukaryotic cell lines
The following cell lines were used: glucagon-producing Golden Hamster pancreatic
tumor cell line, InR1G9 (A-cell phenotype) (Takaki et al. 1986); human
choriocarcinoma cell line, JEG-3  (Kohler and Bridson 1971).
2.14 Tissue collection
Brain, cerebellum, eye and whole pancreas or pancreatic islets were collected from
wild type mice strain Bar Harbor CF1. Tissues were immediately frozen in liquid
nitrogen and stored at –80°C.
2.15 Antisera and antibodies
Pax6 (C-20) goat polyclonal IgG (Santa Cruz Biotechnology, Heidelberg)
Anti-goat IgG-HRP (Santa Cruz Biotechnology, Heidelberg)
Anti-Pax6 serum (Turque et al. 1994)
2.16 Molecular weight standards
DNA standards
λ-DNA digested with HindIII/EcoRI (Pharmacia, Freiburg) and “20 bp ladder”
(Invitrogen, NV Leek).
Protein Standards
For SDS PAGE analysis pre-stained protein weight standard (Sigma, Munich) with
the size range 205, 112, 87, 69, 56, 38,5,  33.5 kD were used.
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2.17 Standard  methods for handling RNA and DNA
Sterilisation
Glassware and solutions which required inactivation of microorganisms, proteases or
nucleases were autoclaved under following conditions: 20 min, 120°C, 105 Pa. Heat-
labile substances (i.e. antibiotics, SDS, PEG) were prepared with sterile water or
were sterilized by filtration (Minisart-Filters, Sartorius, Göttingen).
Phenol-chloroform extraction
Protein impurities were removed by vigorous shaking of DNA solution with equal
volume of phenol/chloroform/isoamyl alcohol mixture (25:24:1). Emulsion was then
centrifuged (1min, RT, 14000 rpm), and upper aqueous phase was collected for DNA
precipitation.
DNA/RNA precipitation
DNA was precipitated by addition of NaAc (final conc. 0.3 M) and one volume of
isopropanol. The mixture was then vortexed and centrifuged (5 min, 4°C, 14000
rpm). The pellet was washed with 70% ethanol and centrifuged (5 min, RT, 14000
rpm). After washing the supernatant was aspirated and the pellet was vacuum dried.
Dried DNA was redissolved in sterile water or TE buffer. RNA was precipitated in a
similar way.  After addition of NaAc and isopropanol the mixture was freezed for 30
min at -80°C. After thawing the mixture was centrifuged (15 min, 4°C, 14000 rpm)
and than washed twice with 80% ethanol as above. After washing the supernatant
was aspirated and the pellet was vacuum dried. Dry pellet was redissolved in RNase
free water or TE buffer.
Dialysis
DNA solutions were put into a dialysis tube (GIBCO/BRL, Karlsruhe), which was then
closed with clips and placed in 1L TE buffer in a container with stirring. Dialysis was
done twice for 12-16 hrs at  4°C.
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Annealing of DNA oligonucleotides
Double-stranded EMSA probes were prepared as follows: in 50 µl volume two single-
stranded oligonucleotides (100 pmol each) and NaCl (final conc. 10  mM) were
mixed.  Using TRIO-Thermoblock (BIOMETRA) the mixture was denaturated for 1
min at 95 °C and then cooled down slowly where each following temperature step
lasted 5 min: 85°C, 75°C, 65°C, 55°C, 45°C, 35°C, 20°C.
Radioactive labeling of DNA oligonucleotides by Klenow “fill-in” reaction
Double-stranded DNA probes possessing 5’-GATC overhangs were labeled using
32P- dCTP and Klenow fragment of DNA Polymerase I. The “fill-in” reaction was set
up on ice in total volume 20 µl:
double-stranded oligonucleotide,  2pmol/µl 1 µl
dNTPs (without dCTP), 1 mM 1 µl
10 x Klenow Buffer (Tris 0.5M, MgCl2 0.1M) 2 µl
Klenow Fragment, 1U/µl 2 µl
α-32P-dCTP, 10 µCi/µl 2 µl
water 12 µl
The reaction mixture was incubated for 1 hr at 37°C.  Unincorporated nucleotides
and salts were removed using Nucleotide Removal Kit (Qiagen, Hilden).  For 20 µl
reaction, 200 µl of binding buffer was added and after 1min incubation the mixture
was applied to QIA-quick column and centrifuged (2 min, RT, 6000 rpm). The flow-
through was discarded and 500 µl of Washing Buffer was applied to the column
followed by centrifugation 2 min, RT, 6000 rpm (flow through discarded). The
washing step was repeated and then column was again centrifuged without addition
of any buffer to dry (2 min, RT, 6000 rpm). Probe was eluted with 20 µl of Elution
Buffer and fraction was collected by centrifugaton: 2 min, RT, 6000 rpm. 1 µl of the
eluate was mixed with 4 ml of Scintillation Liquid (Quicksafe A, Zinser Analytic,
Frankfurt) and measurement of the radioactivity incorporation was done using
scintillation counter (Beckman LS 1801, Munich). The probe was then diluted to final
activity of 20,000 cpm/ µl.
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Estimation of nucleic acid concentration
The concentration of nucleic acids was estimated by measuring absorbtion at 260 nm
using  Shimadzu UV 160-Spectralphotometer (Duisburg). Concentration was
calculated using the OD260=1 for the following amounts of nucleic acids
Double-stranded DNA 50 µg/ml
Single-stranded DNA 20 µg/ml
RNA 40 µg/ml
In addition to OD260 also the absorbtion at 280 nm was measured indicating protein
concentration. DNA or RNA preparations which had ratio of OD260/OD280 in the range
of 1.8-2.0 were regarded as pure and protein-free (Sambrook  et al. 1989).
2.18 Gel electrophoresis
Agarose gel electrophoresis
Analysis of RT-PCR products, restriction enzyme digest, minipreparations of plasmid
DNA or enzymatic modifications of DNA was done with the use of agarose gel
electrophoresis. Agarose gel (0.8 % – 2.5 %) was prepared in TBE buffer by heating
to ca. 60°C, and ethidium bromide (0.5 µg/ml) was added before pouring the gel into
the tray.  Before loading samples were mixed with 6x loading buffer . Electrophoresis
was run in a horizontal apparatus (Bio Rad, Munich) under constant current and
voltage of 5-10 V per 1cm of gel length. After electrophoresis DNA fragments in the
agarose gel containing ethidium bromide were visualised using UV (254 or 366 nm)
transiluminator (Vetter GmbH, Wiesloch) and photographed for archivisation and
analysed using a camera and software set (E.A.S.Y., Wiesloch).
Purification of DNA fragments from agarose gel
DNA fragments were purified after agarose gel electrophoresis using High PureTM
PCR Purification Kit (Boeringer, Mannheim). This procedure allows DNA fragments
separated electrophoretically to be purified from other DNA fragments, salts or
unincorporated nucleotides prior to cloning or other procedures.
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  After electrophoresis the DNA fragment was excised from the agarose gel with
sterile scalpel (band was visualised by UV transiluminator), transferred to sterile E-
tube and mixed with Binding Buffer (300 µl per 1mg of gel). Samples were incubated
for 15 min at 56°C to melt agarose and then vortexed shortly. For fragments shorter
than 300 bp, isopropanol was added (150µl/1mg of gel).  Samples were then
transferred into the High Pure SpinColumns and centrifuged for 30 sec., 14000 rpm,
RT. Flow through was discarded and 500  µl of Washing Buffer was applied to the
columns followed by centrifugation for 30 sec., 14000 rpm, RT. Again the flow
through was discarded and for the second wash 200 µl of Washing Buffer was
applied and then samples were centrifuged as before. To elute the DNA fragment
columns were placed in fresh, sterile E-tubes and 30-100 µl of water or Elution Buffer
was applied. Elution was done by centrifugation of samples for 30 sec., 14000 rpm,
RT.












Radioactively labelled DNA fragments from EMSA were visualised by
autoradiography.  After electrophoresis, the gel was dried under vacuum using gel
dyer (G200, Fröbel, Blaufelden) and placed over Phosphor-Imager screen and
exposed for 16 hrs, RT. Screens were scanned using Phosphor-Imager reader (Fujix
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BAS 1500, Raytest, Straubenhardt) and data subject to software analysis (TINA Data
ReaderTM). Alternatively EMSA gels were subject to autoradiography with use of
Roentgen films (Hyperfilm MP, Amersham, Braunschweg). Exposition was done in
Roentgen cassettes (Kodak X-Omatic) in –80°C for 2-4 days. Development of the
film was done by incubation ca. 15 sec. in developer solution (LX 24, Kodak) then
short wash in water and incubation in fixer solution ca. 15 sec. (AL 4, Kodak). After
final wash in water film was dried.
2.19 RT-PCR
RT-PCR combines reverse transcription of RNA to cDNA performed by reverse
transcriptase followed by PCR amplification of cDNA by DNA Polymerase. This
extremely sensitive  technique allows to detect or/and clone, in form of cDNA, even
very rare mRNA molecules. In this work so called single-tube RT-PCR was
employed, using Gene Amp® Thermostable rTth Reverse Transcriptase RNA PCR
Kit (Perkin Elmer, Langen), to clone cDNA of PAX6 transcriptional factor from
different tissues. Here rTth-DNA-Polymerase was used which in the presence of
Manganium ions (MnCl2) performs reverse transcription reaction primed by a mRNA
sequence-specific primer. After cDNA synthesis the reaction conditions are changed
by addition of Mn+2 chelator and MgCl2. In presence of Mg+2 rTth-DNA-Polymerase
performs DNA synthesis and the PCR is started. General algorythm of the PCR was
as follows: denaturation of template, annealing of primers, elongation of primers with
thermostable DNA-Polymerase. This cycle was repeated 25 to 30 times allowing to
amplify exponentially DNA fragments of interest (derived from PAX6 mRNA). After all
cycles were performed, a final elongation step was included to assure that full lenght
DNA fragments are synthesised. To avoid inefficient reverse transcription reaction
due to secondary mRNA structures, initial denaturation step (5 min, 70 °C) was
included before addition of rTth-DNA-Polymerase (RT MixA). Pipetting, pipette tips
and solutions were kept RNase/DNase  free as were the tubes used (Thin-Walled
PCR Tubes, 500 µl, Boerhinger, Mannheim).
  Typically RT reaction was done as follows: RT Mix A was incubated 5 min at 70°C
(Biometra TRIO-Thermoblock with heated cover) and then 5.6 µl of RT Mix B was
added. RT reaction was run for 15 min at 60°C in Biometra TRIO-Thermoblock with
heated cover. In parallel negative control reaction without RT step was done by
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incubating samples for the same time on ice. After RT reaction step samples were
cooled on ice (5 min) and 80 µl of PCR Mix was added to each. PCR was run
according to profiles in Tab. 3.
Primer Pair    Denaturation     PCR cycles profile                Cycles       Elongation
2up/6down     94°C/4min     95°C/30sec., 58°C/1min, 72°C/3min      35          72°C/5 min
6up/13down   94°C/5min   95°C/30sec., 59°C/1min, 72°C/2min        40          72°C/5 min
Tab. 3. PCR temperature profiles. Summary of primer pairs and PCR profiles used to
amplify fragments of PAX6 cDNA covering the whole protein coding sequence. Two regions
were amplified: one containing exons 2-6, and second exons 6-13 with overlapping region in
exon 6.“Primer Pair” - see 2.9.1 for sequences. “Denaturation” – temperature and time of
initial DNA denaturation before starting main PCR cycles. “Cycles” – number of cycles in
PCR protocol. “Elongation” – temperature and time of final elongation step after all PCR
cycles.
RT Mix A    final conc.
10 x RT Buffer
(Tris-HCl (pH 8.3) 100  mM, KCl 900  mM) 2 µl 1x
“Down” Antisense Primer (60µM) 0.25 µl 0.75 µM
total RNA x µl 200 ng
Ampuwa ad 14.4 µl
RT Mix B final conc.
MnCl2 (10  mM) 2 µl 1 mM
dNTPs (each 10  mM) 1.6 µl each 200µM
rTth-DNA-Polymerase (2.5 U/ µl)  2 µl 5U/20 µl
PCR Mix final conc.
10x Chelating Buffer 8 µl 0.8x
MgCl2 (25 mM) 4 µl 1 mM
“Up” Sense Primer (60µM) 0.25 µl 0.15 µM
Ampuwa ad 80 µl
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After the RT-PCR reaction, the products (20-50 µl) were analysed by agarose gel
electrophoresis (2.18). Specific product(s) were excised from gel and DNA was
purified (2.18) for cloning into pCR2.1 T vector (Invitrogen, NV Leek).
2.20 Enzymatic modification of DNA
“Addition of single A”
RT-PCR products after purification from agarose gel were subject to cloning using
“T/A” system: Taq DNA polymerase catalyses template-independent single A
nucleotide addition to RT-PCR product (rTth-DNA-Polymerase does not poses this
activity). This single A “overhang” anneals with single T of linearised vector (pCR2.1
T) and facilitates cloning (ligation is performed by Topo Isomerase bound to vector
termini). Reaction was performed in total volume of 15 µl:
“Addition of single A” Reaction
purified from gel RT-PCR product 11.5 µl
10x PCR Buffer (Perkin Elmer) 1.5 µl
Taq DNA Polymerase (4U/µl) 0.5 µl
dATP (10 mM) 1.5 µl (final conc. 1 mM)
Reaction was incubated for 30 min at 72°C and 4 µl were directly used for T/A TOPO
cloning (see below).
Endonuclease restriction
Usually restriction digest was performed for 3-10 hrs at 37°C using buffers and
enzymes commercially available (MBI, Pharmacia) in total volume of 20-50 µl. 1-2 U
of restrictase was used per 1µg of DNA. The volume of restriction enzymes in the
reaction was not greater than 10% of the total volume.
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Ligation of DNA fragments
Ligation of double-stranded DNA fragments (after restrictase digest) was performed
with T4-DNA-Ligase. This enzyme performs ATP-dependent phospho-di-ester bond
catalysis between 3’-hydroxyl and 5’-phosphate ends (“sticky” or “blunt”). DNA
fragments were added in molar ratio vector to insert of 1:5-50 respectively. Ligation
reaction was usually incubated for 16-20 hrs at 10-16°C. In 20 µl of total volume were
mixed:
T4-DNA-Ligase ligation
10x Buffer (MBI Fermentas) 2 µl
ATP (2  mM) 0.5 µl
DNA fragments x µl
T4-DNA-Ligase (1U/µl) 4 µl
water ad 20 µl
In case of T/A TOPO cloning system (Invitrogen, NV Leek) reaction was incubated in
RT for 5 min (according to manual) and contained: 4 µl of RT-PCR reaction and 1 µl
of pCR2.1 TOPO T-Vector (Invitrogen). Ligation reaction was directly used to
transform bacteria.
2.21 Standard  methods of molecular cloning
Preparation of competent E.coli bacteria
Competent bacteria are produced by modification of cell wall which facilitates DNA
uptake. 100 ml of LB medium was inoculated with single colony of E.coli strain
HB101 (from stock plate) and culture was grown at 37°C, 200 rpm till OD600=0.6.
Bacteria were centrifuged (10 min, 4°C, 3000 rpm) and the pellet was resuspended in
50 ml of sterile 50 mM CaCl2 solution (4°C) and incubated on ice for 30 min. The
suspension of bacteria were centrifuged (10 min, 4°C, 3000 rpm) and the pellet was
resuspended in 10 ml of sterile 50 mM CaCl2 (4°C) with 15% glycerol. The mixture
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was dispensed into aliquots of 100 µl and stored at –80°C. Competent TOP10F´and
BL21(DE3)pLys bacteria were purchased from Invitrogen, NV Leek.
Transformation of competent bacteria
Transformation of TOP10F´ bacteria was done by gentle mixing of one aliquot (50 µl)
with 2 µl of 0.5 M ß-ME and 2-3 µl of ligation reaction (RT-PCR products cloning with
T/A TOPO system). After incubation for 30 min on ice bacteria were heated for 45
sec. at 42°C, cooled for 3 min on ice and 300 –µl of LB medium was added. Bacteria
were incubated at 37°C, 200 rpm, 1hr to allow antibiotic resistance expression and
were plated out on  LB-agar plates containing Amp 50µg/ml, IPTG 1 mM and X-Gal
40mg/ml to allow “Blue-White” screening. Transformation of HB101 – used for
standard cloning procedures – was done in a similar way. LB-agar plates did not
contain IPTG and X-Gal. In case of BL21(DE3)pLys, 50 µl aliquot was mixed with 2 µl
of 0.5 M ß-ME and 5-10 ng of construct DNA (GST-PAX6 fusion protein construct)
and incubated on ice 30 min. Bacteria were heated for exactly 30 sec. at 42°C and
quickly cooled on ice (3 min). Then 250 µl of prewarmed SOC medium was added
and bacteria were incubated in shaking incubator at 37°C, 225 rpm for 1 h The whole
transformation mixture was then used to inoculate 50-100 ml of LB medium
containing 100µg/ml amp. 34µg/ml of CA was added in the pilot culture for induction
study or maxi scale culture for fusion protein isolation.
Mini preparation of plasmid DNA
A modified alkaline lysis method was used (Le-Gouill et al. 1994) to purify plasmid
DNA. A single colony was inoculated into 5 ml of LB amp medium and grown for 10-
16 hrs at 37°C, 225 rpm. Then bacterial culture was subject to the following protocol:
1. 1.5 ml of culture was centrifuged of (4°C, 6000 rpm, 5 min), Eppendorf 5415C.
2. The pellet  was resuspended in 100 µl of SOLUTION I.
3. 200 µl of SOLUTION II was added (the tube was carefully inverted to mix) and
200 µl of chloroform was added.
4. After 1 min of lysis 150 µl of  ice cold SOLUTION III was added and the mixture
was vortexed for 2 seconds.
5. The mixture was centrifuged  (RT, 14000 rpm, 2 min).
Materials  and  methods
29
6. The upper phase was taken (about 360 µl) and was precipitated with 1 vol. of
100% isopropanol.
7. The mixture was centrifuged  (4°C, 14000 rpm, 5min) and after this the
supernatant was discarded.
8. The pellet was washed twice with 80% Et-OH and then dried under vacuum.
9. Dry pellet was redissolved in 20 µl of RNAse I solution (1µg in 1 ml of TE buffer)
and incubated at 37°C for 1 hr (RNA digestion).
10. Plasmid DNA was stored at 4°C.
Solution I: 50 mM glucose, 10 mM EDTA, 25  mM Tris-HCl, pH 8.0
Solution II: 0.2 N NaOH, 1% SDS
Solution III: 29.4 g KAc, 5 ml HCOOH and water to 100  ml
“Maxi” preparation of plasmid DNA
Large amounts of plasmid DNA (1-2 mg) were produced using preparative
ultracentrifugation of bacterial lysate in a CsCl gradient. The protocol was as follows:
1. 15 ml of LB+amp medium (final amp concentration 50 ng/ml) was inoculated with
a  single colony.
2. The culture was grown overnight  in a rotary shaker (225 rpm, 37°C).
3. 1 liter of a LB+amp medium was inoculated with 10 ml of the overnight culture
(rest of the overnight culkture was kept for reference).
4. The 1 liter culture was grown at 37°C until the OD600 = 0.8 – 1.0 and then CA was
added to final concentration of 200mg/L. The culturte was further incubated in
rotary shaker (225 rpm, 37°C) for additional 10-12 h.
5. The 1 liter culture was centrifuged at 10000 rpm (Beckman JA-14 Rotor) for 15
min at 4°C.
6. The pellet was resuspended in 45 ml ice-cold STE ( 25% saccharose, 1 mM
EDTA, 50 mM TRIS pH 8.0) and 3 ml of  lysozyme (60mg/ml STE) was added.
7. After ncubation for 20 min on ice, 3.6 ml of 0.5M EDTA was added and the
mixture was incubated for 5min on ice. Then 28.8 ml of Triton-mix was added
(0.1% Triton X-100,   50 mM Tris  pH 8.0,   60 mM EDTA).
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8. The mixture was incubated  30 min on ice (shaking every 5min).
9. The mixture was centrifugated for 1 hr, at 16000 rpm (Beckman JA-20 Rotor) at
4°C.
10. To the supernatant 40 ml of 30%PEG was added (30%PEG 6000, 1.5M NaCI),
and the mixture was incubated for 1 h on ice.
11. The mixture was centrifugated for 10 min, 10000 rpm (Beckman JA-14 Rotor) at
4°C and the supernatant was discarded.
12. The pellet was resuspended in 10 ml of TNE buffer (10 mM Tris pH 8.0,  10 mM
NaCl,  1 mM EDTA) and  10.9 g of CsCl plus 150 µl of ethidiumbromide
(10mg/ml) was added.
13. The solution was pipetted into an ultracentrifuge tube and weighted. The
difference between the tubes were not more than 0.05 g.
14. The tubes were centrifuged (20 hrs, 60000 rpm, 20°C) (Beckman Ultracentrifuge
L5-65, 70 Ti-Rotor).
15. The band containing plasmid DNA was recovered with syringe and niddle.
16. The Et-Br from the DNA solution was extracted several times with equal volumes
of isoamyalcohol untill the solution was colorless.
17. The clear solution was put into dialysis tubings and dialysed twice at 4°C against
TE (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0) to remove CsCl.




Sequencing was done using Thermo Sequenase Fluorescent Labelled Primer Cycle
Sequencing Kit (Amersham-Pharmacia, Braunschweg). This kit  combines
conventional dideoxy sequencing reactions (Sanger et al. 1977) with thermal cycling
conditions to generate high quality sequences from very small amounts of template
DNA.  The use of thermostable Taq DNA polymerase makes it possible to repeatedly
cycle the template through alternating periods of heat denaturation, annealing and
polymerization at elevated temperatures.  Under these conditions, the purity and
quantity of starting template are less critical, with single colonies or plaques often
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providing sufficient template for use.  The elevated temperatures inhibit reannealing
of linear double-stranded DNA templates, such as PCR products, thus improving the
effective amount of template available for reaction.  False stops are also less
frequent since annealing and polymerization are both performed at elevated
temperatures, where the stringency of primer hybridization is greater and secondary
structure of the template is reduced. Fluorescent labelled (5’-IRD-800) sequencing
primers allow to read the sequence using laser scanner. Typically 4 µl reaction
contained:
Plasmid DNA (40-80 ng/µl) 2.5 µl
Sequencing Primer (1pmol/µl) 0.5 µl
A/C/G/T reagent (Amersham) 1 µl (different  in each reaction)
Components were pipetted on ice into “Thin-Walled PCR Tubes” (Boerhinger,
Mannheim) and overlayed with mineral oil (Sigma, Munich). Reaction was done in
Biometra TRIO-Thermoblock according to following PCR temperature profiles
depending on sequencing primer used:
5’-IRD-800-Primer    Denaturation                      Temperature profile                         Cycles
M13reverse     95°C/5min         95°C/30sec.,  60°C/20sec.,  70°C/45sec.          30
T7promoter     95°C/5min         95°C/30sec.,  55°C/20sec.,  70°C/45sec.          30
CMVpromoter     95°C/5min         95°C/30sec.,  57°C/20sec.,  70°C/45sec.          30
Luciferase gene        95°C/5min         95°C/30sec.,  49°C/20sec.,  70°C/45sec.          30
Tab. 4. Temperature profiles of the cylic sequencing reactions. The primers used for
sequencing reaction are indicated. Also are shown the temperatures, the times for each step
and the number of cycles.
Samples of the sequencing reaction were mixed with 1 µl of Sequencing Stop Buffer
(Amersham-Pharmacia, Braunschweg) and denatured for 3 min before loading on
the sequencing polyacrylamide gel.
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Sequencing polyacrylamide gel electrophoresis
To separate DNA fragments with very small molecular weight differences (single
nucleotide) as is required in the sequencing, a denaturing polyacrylamide gel
electrophoresis was used with urea as a denaturing agent. The gel was prepared
using SequaGel XR-Acrylamide kit (Biozym, Hess. Oldendorf) in total volume of 40
ml:
SequaGel XR-Acrylamid solution 32 ml
SequaGel complete buffer reagent 8 ml
DMSO 400 µl
APS (10%) 300 µl
After addition of APS the gel mix was poured in to a casting frame (Biozym, Hess.
Oldendorf) with 0.25 mm spacer thickness, and allowed to polymerise for ca. 2 h.
After polymerisation the gel was fixed onto sequencing apparatus (Li-Cor 4000,
MWG-Biotech, Ebersberg) and pre-run for 30 min (1500V) to achieve the denaturing
temperature (50°C). 4 µl of the sequencing reaction with 1 µl of the loading buffer
(USB/Amersham, Braunschweg) were denaturated (95°C, 3 min) and directly loaded
into the gel. Electrophoresis was run in 1x TBE buffer under 1500V for ca. 16 h. The
sequences was automatically scanned by sequencing laser (fluorescently labelled
sequencing primers were used). Reading of sequence was done by software
attached to the sequencer (Data Collection, Li-Cor Inc., Lincoln, USA). The
sequences were analysed further by the GCG software package (2.30).
2.23 RNA isolation from animal tissues
Pax6 transcript analysis by RT-PCR was performed using total RNA isolated from
murine tissues: whole brain, cerebellum, eye, whole pancreas, pancreatic islets. The
embryonic poly (A)+ RNA was also used which was obtained from Luc St-Onge
(Develogen, Göttingen). Total RNA purification was done with the RNeasy Mini Kit
(Qiagen, Hilden). 20-80 mg of frozen (-80°C) tissue was used. Following protocol
from the Qiagen manual was used:
1. The frozen tissue was homogenised by mortar and pestle in liquid N2. Tissue
powder was transferred into N2-cooled, E-tube. The liquid N2 was let to evaporate.
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2. A 1.9 ml of the Buffer RLT was added to lyse the homogenate. After vortexing for
5 sec. the lysate was applied on the QIAshredder Spin Column (further
homogenisation) and centrifuged  (2 min at 4°C, 14000 rpm) (Eppendorf 5415C).
3. The flow-through from the QIAshredder Spin Column was centrifuged for 5 min,
14000 rpm, 4°C and the supernatant was taken for further steps.
4. A 1 volume of 70% ethanol was added to the supernatant (ca. 1.9 µl) and after
vortexing for 5 sec. the mixture was applied on the RNeasy Spin Column. The
column was centrifuged for 5 min at RT, 14000 rpm and flow-through was
discarded.
5. A 3.8 ml of the Buffer RW1 was applied and the column was again centrifuged (as
before) to wash.
6. The same washing step was repeated twice with 2.5 ml of the Buffer RPE. After
the second wash column was centrifuged empty to let it dry.
7. Elution of RNA was done twice with 30 µl of sterile, RNase-free water (column was
let standing for 1 min and then centrifuged for 5 min, 14000 rpm at RT).
8. Concentration and purity of total RNA preparation was estimated
spectrophotometriacally by measuring OD260/OD280 ratio (Shimadzu UV –160
Spectrophotometer). Aliquots of 10 µl were stored at –80°C.
Composition of buffers is patent pending and was not published by Qiagen company.
2.24 Protein expression in bacteria
Full length PAX6 and PAX6 Paired Domain GST fusion proteins were cloned and
bacterially expressed using GST Gene Fusion Vector – pGEX-2T, and
BL21(DE3)pLys strain of E. coli. This system is designed for inducible, high-level
intracellular expression of proteins as fusions with Schistosoma japonicum
glutathione S-transferase (GST). All of the GST Gene Fusion Vectors (pGEX-2T)
include the following features: a tac promoter for inducible, high-level expression, an
internal lac Iq gene for use in any E. coli host. Additionally these vectors encode
thrombin, factor Xa or PreScission Protease recognition sites for cleaving the desired
protein from the fusion product.  Collectively, the pGEX vectors provide all three
translational reading frames beginning with the EcoR I restriction site. The GST
moiety provides an affinity tag for fusion protein purification using Glutathione
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Sepharose 4B.  Highly pure proteins are eluted under mild conditions which preserve
protein antigenicity and functional activity. The following characteristics of the pGEX
system was described by its producer (Amersham / Pharmacia): Induction: tac
promoter is inducible with 1-5 mM IPTG. Expression: Proteins are expressed as
fusion protein, with the 26-kDa glutathione S-transferase (GST).  The GST gene
contains an ATG and ribosome-binding site and is under control of the tac promoter.
A translation terminator is provided in each reading frame.  The resulting fusion
protein can be purified using the GST Purification Module. Host(s): E. coli. The
plasmid provides lac Iq repressor; supplied with E. coli BL21. Selectable marker(s):
Plasmid confers resistance to 100 µg/mi ampicillin. The GST-Pax6 full lenght fusion
protein was bacterially expressed and purified according to the following protocol:
1. Freshly thawed BL21(DE3)pLys E.coil bacteria were transformed with pGEX-2T-
PAX6 FL (GST-Pax6 full lenght vector) as described 2.20.
2. A 300 µl of transformation mixture was inoculated to 20 ml of LB medium
containing 100 µg/ml ampicillin and 34µg/µl chloramphenicol. Culture was grown
for 12 hrs, 37°C, 225 rpm.
3. The 20 ml culture was used to inoculate 1L of LB medium with amp, CA as above
and was grown till OD600=0.6. Reference sample (non-induced) of 1 ml was taken
and culture was induced with IPTG to final concentration of 1 mM. After IPTG
induction culture was further grown for additional 4 hrs at 37°C, 200 rpm.
4. Culture was centrifuged to harvest bacteria for 15 min, 3500 rpm, 4°C (Beckman
JA20 Rotor) and pellet was resuspended in ice-cold 1x PBS Buffer (containing 1
mM DTT and 1 mM PMSF). Suspension was frozen and stored overnight at –
80°C.
5. Frozen bacterial suspension was slowly thawed on ice for ca. 3 hrs and
sonicated 10 x 20 sec. pulses of 400W (Labsonic 1510, Braun, Melsungen).
Sonication was done on ice-water with 30 sec. intervals between sonicating
pulses to avoid sample overheating.
6. To homogenate NP-40 detergent was added to final concentration of 0.2 % and
sample was agitated at rocking platform (Mini Rocking Platform, Biometra,
Göttingen) for 30 min at RT. Reference sample of 500 µl was taken.
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7. Lysate was centrifuged for 10 min, 10000 rpm, 4°C (Beckman JA20 Rotor). 10 µl
reference samples from pellet and supernatant were taken.
8. Supernatant was taken and 1 ml of the prehydrated Glutathione Agarose Slurry
(Sigma, Munich) was added. DTT was added to final concentration of 5 mM.
9. Suspension was agitated at rocking platform for 12 hrs min at 4° and then
suspension was centrifuged for 2 min, 2000 rpm, RT (Heraeus Megafuge 1.0).
10. Pellet of agarose beads was washed by resuspension in 10 ml of ice-cold 1x
PBS Buffer (containing 1 mM DTT and 1 mM PMSF) and centrifugation for 2 min,
2000 rpm, RT. Washing was repeated two more times. At each washing step 10
µl reference sample was taken.
11. Pellet was resuspended  in 2-3 ml of 1x PBS Buffer and transferred in to a
chromatography column (Poly-Prep Chromatography Columns, Bio-Rad, Munich)
and let to sediment for 15 min, RT.
12. Column was opened and eluted twice with 1.5 ml of Elution Buffer collecting 200
µl fractions.
13. Each fraction was then colorimetrically assayed for protein content: 5 ml of each
fraction was mixed with 100 µl “Coomasie Brilliant Blue” –G 250- Reagent (Bio-
Rad, Munich) and each saple pipetted into micro-well plate (96). After 10 min of
colour development, the elution profile was estimated and fractions with the most
protein content were pooled.
14. Pooled fractions were placed in dialysis tubing and dialysed twice against
Dignam D Buffer for 2 hrs, 4°C.
15. After dialysis protein concentration was estimated using “Coomasie Brilliant Blue”
–G 250- Reagent and BSA standard concentration/absorbtion  plot. Samples
were stored at –80°C.
Dignam D Buffer
HEPES (pH 7.5) 20 mM
Glycerol 20% (v/v)
KCl 0.1 M
EDTA (pH 8.0) 0.2 mM
DTT 0.5 mM
PMSF 0.5 mM
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Elution Buffer (pH 7.7)
Glutathione 40 mM
Tris (pH 8.0) 100 mM
NaCl 120 mM





800 mg of Glutathione Agarose (Sigma, Munich) was suspended in 10 ml of water to
hydrate (3 hrs, 4°C) and then agarose was washed twice with 10 ml of 1xPBS and
resuspended in 10 ml of ice-cold 1x PBS Buffer (containing 1 mM DTT and 1 mM
PMSF). The glutathione agarose sluryr was stored at 4°C.
2.25 Extraction of nuclear proteins (Schreiber-Schaffner method)
Nuclear proteins were isolated from the InR1G9 cells. Per sample 60 mm, fully
confluent plates were used. The following protocol was used:
1. A 6-cm plate was  washed with 5-8 ml ice-cold TBS Buffer.
2. Cells were removed by scraping in 2 ml of ice-cold TBS Buffer and transferred to
15 ml tube (Blue Max, Falcon, UK).
3. Plate was washed again with 8 ml TBS Buffer and the cell suspension was added
to the same 15 ml tube.
4. Cells were centrifuged for  2 min, 1600 rpm, RT (Heraeus Megafuge 1.0).
5. Pellet was resuspended in 1 ml ice-cold TBS Buffer, transferred to E-tube and
centrifuged for 2min 1600 rpm, 4°C (Eppendorf 5415C).
6. Pellet was resuspended in 400 µl  ice cold BUFFER A and incubated for 15min
on ice.
7. 25  µl of 10% NONIDET p40 was added and sample was vortexed for 10 sec.
8. Sample was centrifuged for 2 min, 6000 rpm, 4°C (Eppendorf 5415C) and
supernatant containing cytoplasmatic fraction was discarded.
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9. Pellet was resuspended in  50 µl  ice-cold BUFFER C and shaken on rotary
shaker 300rpm, 4°C for 20min.
10.  Sample was centrifuged for 4min, 14000 rpm, 4°C.
11.  Supernatant was collected (ca. 55 µl) and stored in -80°C.
For Western blot analysis 15 µl from the above sample were used. In case of EMSA
1-3  µl of freshly prepared extracts were used.
 
 
                     Buffer A                  Buffer C
 HEPES pH 7.9 10 mM HEPES pH 7.9 20 mM
 KCl 10 mM NaCl 400 mM
 EDTA 0.1 mM EDTA 1 mM
 EGTA 0.1 mM EGTA 1 mM
 DTT 1 mM DTT 1 mM
 PMSF 0.5 mM PMSF 1 mM
TBS Buffer: 8g NaCl, 0.2g KCl, 3g TRIS were dissolved in 800 ml water. pH was
adjusted to 7.4 (HCl) and water added  to 1000 ml.
 
2.26 SDS-polyacrylamide gel electrophoresis
Analytical SDS gel electrophoresis of proteins is carried out in polyacrylamide gels
under conditions that ensure dissociation of the proteins into their individual
polypeptide subunits and that minimize aggregation.  The strongly anionic detergent
SDS is used in combination with a reducing agent (ß-ME) and heat to dissociate the
proteins before they are loaded on the gel.  The denatured polypeptides bind SDS
and become negatively charged.  Because the amount of SDS bound is almost
always proportional to the molecular weight of the polypeptide and is independent of
its sequence, SDS-polypeptide complexes migrate through polyacrylamide gels in
accordance with the size of the polypeptide. By using markers of known molecular
weight, it is therefore possible to estimate the molecular weight of the polypeptide
chain(s). In most cases, SDS-polyacrylamide gel electrophoresis is carried out with a
discontinuous buffer system in which the buffer in the reservoirs is of a different pH
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and ionic strength from the buffer used to cast the gel. After migrating through a
stacking gel of high porosity, the complexes are deposited in a very thin zone (or
stack) on the surface of the resolving gel.  The ability of discontinuous buffer systems
to concentrate all of the complexes in the sample into a very small volume greatly
increases the resolution of SDS-polyacrylamide gels. The sample and the stacking
gel contain Tris-Cl (pH 6.8), the upper and lower buffer reservoirs contain Tris-glycine
(pH 8.3), and the resolving gel contains Tris - Cl (pH 8.8). All components of the
system contain 0.1% SDS (Laemmli 1970). In this study 4% “stacking” gel and 10%
resolving gel were prepared and electrophoresis was run in Mighty Small-System
apparatus,SE 250 (Hoefer , San Francisco) in 1x Tank Buffer at constant current of
170 mA. Before loading the protein samples were mixed with Loading Buffer and
denatured by incubation for 5 min at 95-100°C (boiling water bath). Per lane 15-17 µl
of samples were loaded. After electrophoresis gel was stained with Coomasie-Blue
Solution for 4-10 hrs at RT. Destaining was done by incubation in Destain Solution
for 4-8 hrs changing the solution 3-5 times. Destained gel was dried by sealing it
between porous cellophane sheets (Pharmacia, Hoefer, San Francisco) and letting
stand at RT for 12 h.
10% Separating Gel
Acrylamide Mix 3.33 ml
Resolving Buffer (1.5M Tris pH 8.8) 2.5 ml
Water 4 ml
10% SDS 100 µl
10% APS (0.1g/1ml) 100 µl
TEMED 6 µl
4% Stacking Gel
Acrylamide Mix 0.67 ml
Stacking Buffer (0.5M Tris pH 6.8) 1.25 ml
Water 2.98 ml
10% SDS 50 µl
10% APS (0.1g/1ml) 50 µl
TEMED 2.4 µl













Tris (pH 8.3) 25 mM
Glycine 192 mM
SDS 0.1%
2.27 Western blot analysis
In Western blotting electrophoretically separated components are transferred from a
gel to a solid support and probed with antibodies that react specifically with antigenic
epitopes displayed by the target protein attached to the solid support. In Western
blotting, the samples to be assayed are solubilized with detergents and reducing
agents, separated by SDS-polyacrylamide gel electrophoresis (2.25), and transferred
to a solid support (usually a nitrocellulose filter). The filter is subsequently exposed to
unlabeled antibodies specific for the target protein.  Finally, the bound antibody is
detected by one of several secondary immunological reagents ( 125 I-labeled protein
A or anti-immunoglobulin, or anti-immunoglobulin or protein A coupled to horseradish
peroxidase or alkaline phosphatase).  As little as 1-5 ng of an average-sized protein
can be detected by western blotting. The following protocol was used:
1. InR1G9 cells were splitted the day before insulin treatment. The fully confluent, 6-
cm plates were used for each time point. 1 hr before the insulin treatment the
FCS-containing medium was withdrawn and a new medium with BSA and
antibiotics was applied. Insulin was added in the desired intervals to each 6-cm
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plate. After the insulin stimulation nuclear extracts were prepared as described
(2.25). The nuclear extract samples were separated by SDS-PAGE (15 µl of
extract loaded) (2.26) and the proteins were subject to Western blot.
2. The SDS gel was incubated for 20 min in Buffer C. In this time membrane used
for blotting (Hybond-ECLTM, Nitrocellulose, Amersham) was incubated for few
seconds in water and then for 15 min in Buffer B.
3. Proteins were electroblotted from the gel to the membrane using dry
electroblotting apparatus (Scientific Equipment Workshop, Clinics of Goettingen
University) under constant current of 70 mA for 1.5-2 h The arrangement of
blotting stack was as follows (from “+” –bottom to “-“ –top electrode): 2x
Whattman Paper in Buffer A, 2x Whattman Paper in Buffer B, membrane (in
Buffer B), gel (in Buffer C), 4x Whattman Paper in Buffer C, 15-30x Whattman
Paper (dry).
4. After electroblotting the membrane was blocked (unspecific protein binding) by
incubation for 2 hrs at RT in Blocking Solution. Membrane was then washed
three times in TBST Buffer for 20 min at RT (Mini Rocking Platform).
5. Primary Pax6 antibody (goat polyclonal IgG, Santa Cruz Biotechnology, Santa
Cruz) was applied to membrane (diluted in TBST 1:600, final concentration 0.33
µg/ml). Incubation was done for 16 hrs, 4°C  (Mini Rocking Platform).
6. Membrane was then washed three times in TBST Buffer for 20 min at RT (Mini
Rocking Platform). Membrane was incubated with secondary antibody: anti-goat
IgG-HRP (coupled to Horse Radish Peroxidase) which was diluted in TBST
Buffer 1:15000 (final concentration 6.67 ng/ml). Incubation was done for 30 min,
RT.
7. Membrane was then washed three times in TBST Buffer for 20 min at RT (Mini
Rocking Platform).
8. The blot was visualised using ECL Western Blotting System – Amersham-
Pharmacia, Vienna (HRP-catalysed  chemiluminescence detection). Shortly, the
membrane was incubated for 1 min in 5 ml of developing mixture (2.5 ml Solution
A and 2.5 ml Solution B) and then was wrapped in Saran foil and exposed to
Roentgen films (Hyperfilm MP, Amersham, Braunschweg) for time intervals
ranging from 0.5 to 5 min. The films were developed as described (2.18) and air
dried.
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Buffer A (pH 11.3)
Tris 0.3 M
Methanol 20 % (v/v)
Buffer B (pH 10.6)
Tris 25  mM
Methanol 20 % (v/v)
Buffer C (pH 9.0)
Tris 25  mM
Methanol 20 % (v/v)
Blocking Solution: TBST Buffer with 10% (w/v) Skim Milk Powder (Fluka, Buchs)
TBST Buffer
Tris (pH 8.0) 10 mM
NaCl 150 mM
Tween-20 0.05 % (v/v)
2.28 EMSA (electro-phoretic mobility shift assay)
EMSA technique was used for investigation of protein-DNA interactions. It relies on
the observation that protein-DNA complexes migrate in non-denaturating  acrylamide
gels slower than the free, not protein-bound DNA fragment. In the experiments
nuclear extracts from the InR1G9 cells (2.24) were used as well as the bacterially
expressed GST-PAX6 paired box fusion protein (2.23). The probe was radioactively
labelled using (α-32P)-dCTP.
Binding reaction
The binding reaction was set up on ice in total volume of 20 µl as presented below.
The binding buffer, nuclear extract or bacterially expressed protein plus poly dI/dC
were mixed first and incubated on ice for 10 min. (non-specific competition). Then the
probe was added and incubation was continued for another 15 min. Reaction was
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stopped by addition of 4 µl of 6x Stop Mix and immediately loaded on the non-
denaturing polyacrylamid gel.
Binding Reaction (added as described above)
5x Binding Buffer 4 µl
Nuclear Extract plus water 11 µl
Poly dI/dC (1µg/µl) 4 µl
Probe (20000 cpm/µl) 1 µl
1x Binding Buffer:          
Hepes, pH 7.9 20 mM
KCl 140 mM




The binding reaction mixture after addition of stop buffer was resolved in the non-
denaturating polyacrylamide, 5% gel (1xTBE). The gel was prepared by pouring the
gel mix in to a set of glass plates (15X10 cm) placed in a gel casting base (SE 600,
Hoefer, San Francisco, USA). The gel was run prior to the loading of the samples for
30 min. After loading the samples, the electrophoresis was run for 1-2 hrs at room
temperature, under the voltage of 180V. Then the gel was transferred on Whattman
paper, wrapped with plastic foil and dried under vacuum (70°C, 1hr). Dry gel was
subject to autoradiography.
5% Gel Composition
38% / 2% Acrylamide/Bisacrylamide 6.25 ml
5xTBE 5 ml
Water 38.5 ml
10% APS 250 µl
TEMED 25 µl
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2.29 Eucariotic cells culture  methods
All procedures with eukariotic cell cultures like culturing and transfection were done
under sterile conditions using sterile hood (Heraeus, Hamburg). Solutions and media
were sterilized by autoclaving or filtration and were prewarmed before use (37°C
water bath). All glassware items like pipettes and bottles were autoclaved, and
bottles with liquids were cleaned each time before placing under the sterile hood by
whipping with 70% isopropanol. All centrifugations of cell suspension during
transfection or propagating procedures were done for 2 min, 1300 rpm at RT
(Megafuge 1.0, Heraeus, Hamburg).
Cell culture
InR1G9 and JEG-3 cell lines were grown in 30  ml of culture medium (2.7) on 15-cm
plates (2.3) in 5% CO2, 97% humidity atmosphere (37°C), in cell culture incubator
(Steri-Kult Incubator, Labotect GmbH, Göttingen). Cells were grown to 80-90%
confluency and then propagated as follows: Plates were washed with 10-15 ml 1x
PBS. Then 3 ml of Trypsin/EDTA (GIBCO BRL, Karlsruhe) was applied to dis-attach
the cells. After incubation for 2-3 min at 37°C, plates were shaken and cells were
washed off from the plate with 10-15 ml of culture medium and transferred to 50 ml
tube (Blue Max, Falcon, Becton). The suspension was centrifuged and the pellet was
resuspended in 10 ml of culture medium and again centrifuged. Cells were
resuspended in 30 ml of culture medium in desired ratio and suspension was plated
out.
DEAE-Dextran transfection
Positively charged DEAE-Dextran forms complexes with negatively charged DNA
which then is taken through the cell plasma membrane. This method was used to
transfect the InR1G9 cells. One 15-cm plate was taken at 80-90% confluency. The
plate was washed with 15 ml of 1x PBS, then 3 ml of Trypsin/EDTA was applied.
After incubation for 2-3 min at 37°C, the plate was shaken to dis-attach the cell. The
cells were washed off with culture medium (containing no serum) and transferred to
50 ml tube (Blue Max, Falcon, Becton). After centrifugation, the cell pellet was
resuspended in 20-30 ml Buffer TD and centrifuged again (wash step). Cell pellet
was then resuspended TD Buffer in amount of 1 ml TD Buffer per 6-cm plate. To the
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cell suspension DEAE-Dextran solution was added (5 µl per 6-cm plate) and after
gentle mixing, cell suspension was transferred to 50 ml tubes containing DNA to be
transfected. After gentle mixing DNA/cell suspension was incubated for 15 min at RT
to allow DNA uptake, and then serum-containing culture medium (1 ml per ml of cell
suspension) was added to stop the transfection. Cells were centrifuged and washed
with culture medium (5-10 ml per tube). After final centrifugation cells were
suspended in culture medium (5 ml per 6-cm plate) and plated out. Cells were
harvested 48 hrs after transfection and luciferase and GFP reporter gene assays
were performed (see below). As control for transfection efficiency and squelching
pGFPtpz-cmv [R] (2.10) was cotransfected (500ng per 6-cm plate). Reporter gene
constructs were transfected in amount of 2 µg per 6-cm plate (otherwise indicated)
and total DNA content was kept constant throughout all groups in a given experiment
by balancing with pBS DNA.
TD Buffer




DEAE-Dextran: 60 mg/ml in water. Sterilised by filtration.
Insulin solution (10 µM)
Porcine Insulin 3 mg/50ml
BSA 100 mg/50ml
Insulin was dissolved in 0.9% NaCl solution (pH 2.8). The pH of the solution was neutralised
by addition of 1N NaOH and then BSA was added. The aliquots of 1 ml were stored at –
80°C.
Calcium phosphate transfection
In this protocol a coprecipitate of DNA and calcium phosphate is formed, which is
taken to the cell through phagocytosis. This method was used to transfect the JEG-3
cells. The cells were splitted from 15-cm culture plates (80-90% confluency)  to 6-cm
plates 20-24 hrs before transfection (one 15-cm plate per 10-12 6-cm plates) and
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grown under standard conditions. DNA/calcium phosphate coprecipitate was
prepared as follows: per 6-cm plate 150 µl of DNA solution (in water) was mixed with
150 µl of 0.5 M CaCl2 solution and after thorough mixing 300 µl of 2x HBS was added
(slowly pipetting and simultaneous vortexing). The mixture was then incubated for 30
min at RT to allow formation of the coprecipitate.  After incubation, the mixture
containing the coprecipitate was vortexed and pipetted to 6-cm plates (600 µl per
plate). Cells were incubated with the DNA/calcium phosphate coprecipitate for 4 hrs
in 5% CO2, 97% humidity atmosphere (37°C), Steri-Kult Incubator (Labortect GmbH,
Gorttingen). Then the precipitate-containing medium was discarded and cells were
washed twice with 5 ml of 1x PBS Buffer. The cells were grown for additional 48 h in
fresh culture medium (5 ml per plate) and then harvested. As control for transfection
efficiency and squelching pGFPtpz-cmv [R] (2.10) was cotransfected (50ng per 6-cm
plate). Reporter gene constructs were transfected in amount of 3 µg per 6-cm plate
and total DNA content was kept constant through all groups in a given experiment by
balancing with pBS DNA.





The InR1-G9 cells were treated with insulin. In a standard procedure, the cells were
incubated for 24 h after transfection in a medium containing FCS and antibiotics.
Then, 23 h before harvesting, the medium was withdrawn and a new medium was
applied containing BSA  and antibiotics. 24 h before harvesting insulin was applied: 5
µl of 10 µM solution per 6-cm plate (final conc. 10 nM) and cells were returned to a
incubator.
  In case of the Western blot or EMSA analysis the cells were treated with insulin in
similar way. After application of the medium with BSA insulin was pipetted in the time
intervals as indicated in a given experiment.
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Cell extract preparation
Cells were harvested 48-50 hrs after transfection. 6-cm plates were washed twice
with 2-3 ml of ice-cold 1x PBS buffer. 1 ml of a “Scraping Buffer” was then applied to
the each 6-cm plate. Cells were scraped with rubber scraper and the cell suspension
was transferred to Eppendorf tubes standing on ice. Each plate was washed with 0.5
ml of “Scraping Buffer” and suspension transferred to the same Eppendorf tube.
Cells were centrifuged for 5 min, 6000 rpm, 4°C (Eppendorf 5415C). The cell pellet
was resuspended in 150 µl of Potasium Phosphate Buffer. Cells were then disrupted
by three cycles of freezing and thawing (liquid nitrogen/37°C water bath). The lysate
was vortexed for 2 sec. and centrifuged (5 min, 14000 rpm, 4°C). The cleared lysate
was directly used for the luciferase or the GFP reporter gene assay (see below).
“Scraping Buffer”
Tris (pH 7.5) 40 mM
NaCl 150 mM
EDTA (pH 8.0) 1 mM
Potassium Phosphate Buffer (pH 7.8)
K2HPO4 100 mM
KH2PO4 100 mM
Luciferase reporter gene assay
Firefly luciferase enzyme catalyses oxydative decarboxylation of luciferin. This
reaction is dependent on Mg2+ ions and ATP, and apart from AMP, CO2 and
oxyluciferine, photons are produced. Light emission depends on the luciferase
concentration, therefore luminometric measurement allows to estimate expression
level of luciferase reporter gene. For the luciferase assay 50 µl of cell extract (see
above) was taken and mixed with 368 µl of Assay Mix in luminometric tubes
(Sarstedt, Nümbrecht). Tubes were vortexed and placed in a luminometer
(AutoLumat LB 953, E&G Berthold, Wildbach), where to each tube Luciferine Mix
was injected and light emission in 560 nm was measured for 20 sec. One tube,
Materials  and  methods
47
containing only Luciferine Mix, served as reference sample to estimate the
background level.
Assay Mix








Glycylglycine (pH 7.8) 25 mM
MgSO4 15 mM
EGTA 4 mM
GFP reporter gene assay
The Green Fluorescent Protein (GFP) mutant (tpz) used in the assay is derived from
jelly fish (Aequoria victoria). When irradiated with UV rays, GFP protein possesses
capability of emission of green light (fluorescent absorption/emission) which is
proportional to its  concentration. In this work a GFP construct was used which is
under control of a constitutive CMV promoter (pGFPtpz-cmv [R]). Transfection of this
GFP construct served as a control of transfection efficiency and to monitor
squelching (non-specific inhibition of luciferase reporter gene activity due to titration
of transcriptional factors by cotransfected expression constructs). For GFP assay 50
µl of cell extracts (see above) were taken and pipetted into microplate (96 K, Greiner
GmbH, Frickenhausen). Microplates were read by FluoroCount (Packard) with
excitation/emission wavelengths of 485 nm and 530 nm respectively.
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2.30 Software
(RT)PCR primer design, restriction mapping analysis, DNA/protein sequence
analysis and databases searching was done using GCG package – “Genetics
Computer Groups”- Software version 9.1 (GCG, Madison).
Statistic analysis and plotting graphs was done with Sigma Stat-Programmes,




3.1 The constructs generated in this study
The constructs which were prepared in this study are summarised below in the Tab.
5. All of these constructs were verified by sequencing. The detailed description of the
cloning strategies is presented in the “Materials and Methods” section (2.10 and
2.11).
          Construct                      Description
-350(mutG3)GluLuc Internal deletion of the G3 element.
-350(mutG1)GluLuc Internal deletion of the G1 element.
-350(mutG1/G3)GluLuc Internal deletion of the G1 and G3 element.
-350(-150/-91)GluLuc Internal deletion of the G4 element.
GAL4-Pax6 The GAL4 DNA-binding domain (amino acids 1-
147) fused to the full length Pax6.
GST-Pax6(FL) The glutathione S-transferase fused N-terminally to
the full length Pax6.
Tab. 5. List of the constructs generated in this study. In the upper part of the table are
shown the glucagon-reporter fusion gene constructs containing the –350 region with an
internal deletion of regulatory element(s). The deletion was done by converting the




3.2 Pax6 gene expression in pancreatic islets as revealed by RT-PCR
In order to analyse Pax6 gene expression a RT-PCR analysis was performed. Two
primer pairs were used, one of which flanks the alternatively spliced exon 5a (Fig. 4).
Fig. 4. Pax6 gene expression in mouse pancreas as revealed by RT-PCR. The upper
part of the figure shows the relative positions of the two primer pairs used. The Pax6 cDNA is
shown with the exons of the human gene. UTR - untranslated region. The sizes of the
expected RT-PCR products are 499 and 457 bp with the primer pair targeting exon 2 and
exon 6 (with and without exon 5a), and 933 bp with the primer pair targeting exon 6 and exon
13. Total RNA from adult or embryonic poly (A)+ RNA (day 11.5/12.0 p.c.) pancreas was
used. The RT-PCR products were verified by subcloning and sequencing.
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With total RNA extracted from adult pancreas (Fig. 4) or from isolated pancreatic
islets (data not shown), the primer pair targeting exon 2 and exon 6 detected pax6
transcripts with and without exon 5a (499- and 457-bp fragment, respectively, Fig. 4).
The primer pair that targets exon 6 and exon 13 (Fig. 4) generated a single product
of expected size (933-bp fragment, Fig. 4). The RT-PCR products were verified by
subcloning (T/A system, Invitrogen) and sequencing.
  Similar results were obtained with poly (A)+ RNA extracted from the embryonic
pancreata on days 11.5/12.0 p.c. (obtained from Luc St-Onge, Develogen,
Goettingen) (Fig. 4). With total RNA extracted from the eye and cerebellum, both
primer pairs generated products of the expected size for both splice variants (not
shown), consistent with published reports of the Pax6 splice variants expression in
the eye and central nervous system (Epstein et al.1994, Walther and Gruss 1991).
3.3 Inhibition by insulin of Pax6-mediated transctriptional activity in InR1-G9
cells
Inhibition by insulin of transcriptional activity conferred by a Pax6 binding site (G3A)
from the glucagon promoter
It has been shown previously  that, as a synthetic minienhancer in front of the
minimal thymidine kinase promoter, four copies of the A domain from the G3
element, which contain a Pax6 binding site, confer strong transcriptional activity
(Wrege et al.1995) in the glucagon-producing islet cell line InR1-G9.
  In this study this is confirmed as four copies of the A domain from the G3 element
raised the transcriptional activity 157±10 –fold (n=6) over that of the thymidine kinase
promoter alone. This G3A-dependent transcriptional activity was inhibited by insulin
(10 nM) by about 30% (Fig. 5). In contrast, three copies of the glucagon CRE or four
copies of the G2 element did not confer insulin responsiveness to this heterologous
promoter (Grzeskowiak et al. 2000).
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Fig. 5. Effect of insulin on the transcriptional activity conferred by the Pax6 binding
site G3A. The plasmids -350GluLuc, pT81Luc, and 4xG3A(T81)Luc were transfected into
InR1-G9 cells, and the cells were treated with insulin (10 nM) as indicated. Luciferase activity
is expressed as percentage of the mean value, in each experiment, of the activity measured
in the respective control (no treatment). Values are means ± SE of three independent
experiments, each done in duplicate. *P<0.005 (Student’s t-test).
Inhibition by insulin of Pax6-mediated activity as revealed in GAL4/viral E1B system
As shown above four copies of G3A domain conferred insulin responiveness to the
heterologous, minimal TK promoter. G3A contains the PISCES motif (Wrege et
al.1995, Beimesche et al.1999, Knepel et al.1991) which binds the paired-domain
transcriptional factor Pax6 (Beimesche et al.1999, Sander et al.1997).
  To examine more directly, whether Pax6-dependent transcriptional activity is
regulated by insulin, the GAL4 system was used. The GAL4 system allowed to avoid
the background of the natively expressed Pax6 in InR1-G9 cells (which was the line
used for experiments). A CMV-driven expression vector was constructed where full
length Pax6 cDNA (without exon 5a) was fused to the GAL4 DNA-binding domain
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(amino acids 1-147). The GAL4 DNA-binding domain is derived from the yeast
transcriptional factor GAL4. The GAL4-Pax6 fusion construct was transiently
transfected into InR1-G9 cell line together with a luciferase reporter gene placed
under control of a minimal, viral E1B promoter and five copies of a GAL4-binding site
(5xGal4(E1B)Luc) (Fig. 6).
Fig. 6. Inhibition by insulin of Pax6 transcriptional activity as determined using the
GAL4 system. Expression vectors encoding GAL4-Pax6 or GAL4-VP16 (1 or 0.5 µg/6-cm
dish, respectively) were transfected into InR1-G9 cells together with the 5xGal4(E1B)Luc
reporter gene (2 µg/6-cm dish), depicted above, and the cells were treated with insulin (10
nM) as indicated. Luciferase activity is expressed as percentage of the mean value, in each
experiment, of the activity measured after cotransfection of GAL4-Pax6 or GAL4-VP16
without insulin treatment. Values are means ± SE of three (GAL4-Pax6) or four (GAL4-VP16)




In this system transcriptional activity of the reporter gene construct, 5xGal4(E1B)Luc,
depends on the binding and transactivation achieved by the GAL4-Pax6 fusion
protein. As shown in Fig. 6, coexpression of the GAL4-Pax6 fusion protein raised
transcriptional activity 68 ± 1 -fold. Insulin inhibited GAL4-Pax6 transcriptional activity
by 30% (Fig. 6). Furthermore, insulin had no effect on the transcriptional activity
conferred by the viral VP16 protein (Fig. 6), which was used as a negative control.
VP16 is a strong, viral transcriptional factor is not involved in the regulation of the rat
glucagon gene transcription (Berk 1999). Insulin did not inhibit the expression of the
GAL4-Pax6 fusion protein as revealed by electrophoretic mobility shift assay (Fig. 7)
and Western blotting (Fig. 8).
Fig. 7. Lack of inhibition by insulin of GAL4-Pax6 expression as revealed by
electrophoretic mobility shift assay. An expression vector encoding GAL4-Pax6 (1 µg/6-
cm dish) was transfected into InR1-G9 cells, and the cells were treated with insulin (10 nM)
for 12 or 18 h or were left untreated. Nuclear extracts were prepared and incubated with a
labelled GAL4 DNA binding site as described in “Materials and Methods” (2.27). The
retarded band is shown, which is recognised by an antiserum directed against the DNA-
binding domain of GAL4 (α-gal4) (Santa Cruz Biotechnology, Heidelberg, Germany). First
lane to the left, no nuclear extract added (probe only).
Fig. 8. Lack of inhibition by insulin of GAL4-Pax6 expression as revealed by Western
blotting. An expression vector encoding GAL4-Pax6 (1 µg/6-cm dish) was transfected into
InR1-G9 cells, and the cells were treated with insulin (10 nM) for 12 or 18 h or were left
untreated. Nuclear extracts from InR1-G9 cells were separated by SDS-PAGE and blotted
onto nitrocellulose filter. The filter was probed with antiserum directed against the DNA-
binding domain of GAL4 (α-gal4, Santa Cruz Biotechnology, Heidelberg, Germany). An
arrow indicates a band which is specific for the GAL4-Pax6 protein.
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3.4 Requirement of Pax6 for inhibition of glucagon gene transcription by
insulin in InR1-G9 cells
Effect of overexpression of the Pax6 paired domain
To further study the role of Pax6 in the repression of glucagon gene transcription by
insulin, a portion of the Pax6 protein (amino acids 1 to 246) was overexpressed,
which contains the paired domain (splice variant without exon 5a) but lacks the
transactivation domain and most of the homeodomain. This splice variant of the Pax6
paired domain has been shown to bind to the PISCES motif (Beimesche et al.1999),
within the G3A and G1 elements of the glucagon gene (Beimesche et al.1999,
Knepel et al.1990, Knepel et al.1991). It was assumed that through competition for
DNA binding, the overexpression of the Pax6 paired domain can prevent
transactivation domain-dependent functions of endogenous Pax6. As a positive
control the construct 4xG3A(T81)Luc was included in this experiment, since it is
driven by a synthetic minienhancer built of four copies of the Pax6 binding site within
G3A, and its activity entirely depends on Pax6 function. As shown in Fig. 9, the
expression of the Pax6 paired domain decreased basal activity of the construct
4xG3A(T81)Luc by 90% and completely abolished negative regulation by insulin.
After transfection of -350GluLuc, the overexpression of the Pax6 paired domain
decreased basal glucagon gene transcription by 70% (Fig. 9). Whereas insulin
inhibited glucagon gene transcription in the controls by 65%, it failed to do so in the
presence of the Pax6 paired domain (Fig. 9). It has been shown in another study
(Grzeskowiak 2000) that four copies of the G2 element confer insulin responsiveness
to the insulin-nonresponsive truncated glucagon promoter (-136GluLuc). The G2
element does not contain a Pax6 binding site, although the nonresponsive, truncated
glucagon promoter does (PISCES within the G1element) (Beimesche et al.1999,
Knepel et al.1990, Knepel et al.1991b, Andersen et al.1999). To examine the role of
Pax6 under this condition, the effect of expression of the Pax6 paired domain on G2-
driven transcriptional activity was studied. As shown in Fig. 9, the expression of the
Pax6 paired domain did not alter basal transcriptional activity of the G2 element in
front of the truncated glucagon promoter. However, the expression of the Pax6
paired domain completely abolished the inhibition of transcription by insulin (Fig. 9).
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Effect of mutations of the Pax6-binding sites within the glucagon promoter
As a second approach to study the role of Pax6 in the repression of glucagon gene
transcription by insulin, the Pax6 binding sites (PISCES motifs) of the glucagon
promoter within G3A, G1 or both were changed and thereby mutated into binding
sites of the yeast transcription factor GAL4 (Fig. 10).
FIG. 9. Effect of overexpression of the Pax6 paired domain on insulin responsiveness.
An expression vector encoding the Pax6 paired domain (Pax6-PD, 5 µg/6-cm dish)  was
transfected into InR1-G9 cells together with -350GluLuc, 4xG3A(T81)Luc or 4xG2(-
136)GluLuc reporter genes (0.5 µg/6-cm dish), and the cells were treated with insulin (10 nM)
or left untreated (control). Luciferase activity is expressed as percentage of the mean value,
in each experiment, of the activity measured after transfection of -350GluLuc or 4xG2(-
136Glu)Luc (without insulin and Pax6-PD). Values are means ± SE of three independent
experiments, each done in duplicate.
Results
57
Fig. 10.  Schematic representation of the wild-type and mutated glucagon reporter
genes. Pax6 binds to the PISCES motifs (pancreatic islet cell-specific enhancer sequence)
within G1 and G3. Bases including the PISCES motif within G1, G3 or G1 plus G3 were
mutated into GAL4 binding sites.
Fig. 11.  Basal activity and insulin responsiveness of the mutant glucagon reporter
genes. Plasmids -350GluLuc, -350(mutG1)GluLuc, -350(mutG3)GluLuc, and -350
(mutG1/G3)GluLuc were transfected into InR1-G9 cells, and the cells were treated with
insulin (10 nM) or left untreated (control). Luciferase activity is expressed as percentage of
the mean value, in each experiment, of the activity measured in the -350GluLuc controls.
Values are means ± SE of three independent experiments, each done in duplicate.
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As shown in Fig. 11, the mutation of the Pax6 binding sites within G3, G1, and G3
plus G1 decreased basal transcriptional activity of the glucagon promoter to 14.1,
4.4, and 1.8% of wild type, respectively, confirming that Pax6 is important for basal
glucagon promoter activity. The remaining low transcriptional activities of the mutant
glucagon promoters were not inhibited by insulin (Fig. 11).
Restoration of the transcriptional activity and insulin responsiveness of the mutated
glucagon promoter by overexpression of GAL4-Pax6
Due to potentially overlapping binding sites, the mutation of the PISCES motifs may
not only abolish Pax6 binding but also affect the binding of additional transcription
factors like cdx2/3 and brain-4 within G1 (Andersen et al.1999, Ritz-Laser et al.1999,
Hussain et al.1997, Jin and Drucker 1996).
FIG. 12. Overexpression of GAL4-Pax6 restores basal activity and insulin
responsiveness of glucagon gene transcription after mutation of the Pax6 binding
sites into GAL4 binding sites. Expression vectors encoding GAL4-Pax6 or GAL4-VP16 (50
or 15 ng/6-cm dish, respectively) were transfected into InR1-G9 cells together with the -
350(mutG1/G3)GluLuc reporter gene, and the cells were treated with insulin (10 nM) or left
untreated (control); for comparison, the wild-type -350GluLuc construct was also transfected
(-350). Luciferase activity is expressed as percentage of the mean value, in each experiment,
of the activity measured in the GAL4-Pax6 or GAL4-VP16 controls. Values are means ± SE
of three independent experiments, each performed in duplicate.
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It was therefore examined whether basal activity and insulin responsiveness of the
glucagon promoter can be restored by Pax6 recruited to the double mutant glucagon
promoter through the GAL4 binding sites.  When an expression vector encoding a
GAL4-Pax6 fusion protein was transfected together with -350(mutG1/G3)GluLuc,
basal transcriptional activity of the doubly mutated glucagon promoter was restored
to a level similar to that of the wild-type promoter (Fig. 12). The expression of GAL4-
Pax6 also conferred insulin responsiveness (Fig. 12). After cotransfection of -
350(mutG1/G3)GluLuc and the GAL4-Pax6 expression vector, insulin inhibited
transcription by 43 ± 1%; this is similar to the inhibition by insulin of the wild-type
glucagon promoter activity (56 ± 3%) (Fig. 12). This effect of GAL4-Pax6 seems to be
specific and also not secondary to the restoration of basal activity, because the
expression of GAL4-VP16 restored basal activity of the doubly mutated glucagon
promoter, which was however not inhibited by insulin (Fig. 12).
3.5 DNA-binding and electro-phoretic mobility of PAX6 proteins after insulin
treatment in InR1-G9 cells
Insulin-induced signalling pathways have been shown to regulate the
phosphorylation and subcellular localisation of transcription factors like FKHR (Rena
et al.1999, Tang et al.1999). To study if similar mechanisms might regulate Pax6-
dependent transcriptional activity of the glucagon gene, experiments were performed
investigating the DNA-binding and protein levels of Pax6 after insulin treatment in the
InR1-G9 cells.
Effect of insulin treatment on Pax6 DNA binding as revealed by EMSA
Negative regulation by insulin of Pax6-dependent transcriptional activity might be
explained by changing DNA-binding properties upon insulin stimulation. To study this
possibility electro-phoretic mobility shift assay (EMSA) was performed.
  Radioctively labelled G3 oligonucleotide was used as a probe, which was shown
previously to bind Pax6 (through domain A) (Sander et al.1997). Nuclear proteins
from the InR1-G9 cells (two different preparations) showed a binding of Pax6 to the
G3 probe (Fig. 13), which was not changed by the insulin treatment (30 and 60
minutes). Specificity of the binding was assessed by using an antiserum directed
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against the paired domain of Pax6, which abolished Pax6 DNA binding (the arrow in
Fig.13). As a positive control bacterially expressed, GST-fused Pax6 paired domain
(PD) was used which is visible as a prominent band migrating below Pax6-specific
band (GST-fused PD is smaller and migrates faster than full length Pax6). These
results show that Pax6 DNA-binding properties are not changed upon insulin
treatment as detected in this EMSA.
Fig. 13. Effect of insulin treatment on Pax6 DNA binding. Radioactively labelled G3
oligonucleotide was incubated with nuclear extracts from InR1-G9 cells treated with insulin
for the time indicated (minutes) or left untreated (two independent experiments shown in
square brackets). Pax6-specific complexes are indicated by arrow as the binding is abolished
by anti-Pax6 serum (α-Pax6) treatment. Bacterially expressed Pax6 paired domain (PD) was
included (2µg) as a binding positive control. First lane to the left - probe only, last lane to the
right - probe with α-Pax6 only. NE - nuclear extract, ns - nonspecific band, f - free probe.
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Effect of insulin on Western blot analysis of Pax6 protein after insulin treatment
Insulin may exert its action on gene transcription through changes in the expression
level of a given transcription factor protein or, as it was shown in case of FKHR (Tang
et al.1999; Rena et al.1999) or AFX (Geert et al.1999), by changes in the
phosphorylation state. Either different level of protein expression or postranslational
modifications in phosporylation state may be revealed using Western blot analysis.
Changes in the band intensity can reflect different protein expression and different
migration properties might be due to differences in the state of phosphorylation after
insulin treatment. Results from Western blot analysis using Pax6-specific antibodies
are shown in the Fig. 14. Nuclear extracts were used from InR1-G9 cells treated with
insulin for 8, 20 and 60 minutes or without insulin. The expression level of Pax6
protein was not changed by insulin treatment. Also no changes in the mobility of
Pax6 protein could be detected.
Fig. 14. Western blot analysis of Pax6 after insulin treatment. Nuclear extracts from
InR1-G9 cells treated with insulin for the indicated time (minutes) were subject to Western
blot analysis. Pax6-specific antibody (α-Pax6 [C-20] goat polyclonal IgG, Santa Cruz
Biotechnology, Heidelberg) was used to detect Pax6 proteins.
3.6 Effect of a mutation of extracellular signal-regulated kinase (ERK) and p38
kinase sites within the Pax6 transactivation domain on the regulation by
insulin.
There is evidence that the transactivation domain (TAD) of Pax6 is a substrate both
in vitro and in vivo for extracellular signal-regulated kinase (ERK) and p38 kinase
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(Mikkola et al. 1999). Three sites were described (Thr323, Ser376 and Ser413), which
after phosphorylation by ERK or p38 kinase stimulated transactivating properties of
Pax6. To test whether these kinases are involved in the regulation of Pax6-
dependent transcriptional activity by insulin, the GAL4 system was used. The GAL4
DNA-binding domain was fused to zebrafish Pax6 TAD where all three ERK/p38
phosphorylation sites were mutated (Mikkola et al. 1999). When cotransfected
together with the mutated glucagon reporter gene, in which both Pax6 binding sites
within G1 and G3 had been mutated into GAL4 binding sites, this ERK/p38-
insensitive mutant (GAL4-TADm3) conferred strong transcriptional activity which was
three fold higher as compared to the activity conferred by the wild type TAD (GAL4-
TADwt).
Fig. 15. Mutation of p38/ERK phosphorylation sites within Pax6 transactivation domain
does not abolish negative regulation by insulin. InR1-G9 cells were transfected with -
350(mutG1/G3)GluLuc reporter gene (2µg/6-cm dish) together with expression vectors (each
100 ng/6-cm dish) encoding following proteins: GAL4-TADm3 (Pax6 TAD with mutated three
p38 kinase/ERK phosphorylation sites), GAL4-TADwt (wild type Pax6 transactivation domain
from zebrafish) and GAL4-Pax6 (full length, wild type Pax6 from mouse). The cells were
treated with insulin (10 nM) or left untreated (control). Luciferase activity is expressed as
percentage of the mean value, in each experiment, of the activity of –350GluLuc (without
insulin). Values are means ± SE of three independent experiments, each done in duplicate.
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The activity of the triple mutant was inhibited by insulin by 55% (Fig. 15). Similar level
of inhibition was also seen in case of the wild type TAD and full length, wild type
Pax6 (GAL4-Pax6wt) constructs, 50 and 54% respectively (Fig. 15).
3.7 Effect of insulin on CBP-mediated transcriptional activity
Effect of insulin on GAL4-CBP activity in the context of the glucagon promoter but not
in the context of viral E1B promoter
Evidence suggests that the p300/CBP proteins may interact with and function as
coactivators of Pax6 (Hussain and Habener 1999). To  test  the hypothesis that CBP,
like Pax6, can confer insulin responsiveness to the glucagon promoter, full length
CBP was fused to the GAL4 DNA-binding domain.
Fig. 16. Inhibition by insulin of GAL4-CBP activity in the context of the glucagon
promoter. An expression vector encoding GAL4-CBP (pGAL-CBP8, 2 µg/6-cm dish) was
transfected into InR1-G9 cells together with -350(mutG1/G3)GluLuc or 5xGal4(E1B)Luc
reporter gene, and the cells were treated with insulin (10 nM) or left untreated (control).
Luciferase activity is expressed as percentage of the mean value, in each experiment, of the
activity measured in the respective GAL4-CBP control. Values are means ± SE of three
independent experiments, each done in duplicate.
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When cotransfected together with the mutated glucagon reporter gene, in which both
Pax6 binding sites within G1 and G3 had been mutated into GAL4 binding sites (-
350(mutG1/G3)GluLuc), GAL4-CBP conferred strong basal activity which was
inhibited by insulin by 40% (Fig. 16). In contrast, when cotransfected with a reporter
construct, in which multiple GAL4 binding sites had been placed in front of the
truncated viral E1B promoter (5xGal4(E1B)Luc), GAL4-CBP conferred transcriptional
activity which was however not inhibited by insulin (Fig. 16).
Effect of insulin on transcriptional activity conferred by N-terminal and C-terminal part
of CBP.
CBP is a large, multimodular protein with many domains interacting with numerous
cofactors and transcriptional factors (Fig. 17) (Glass and Rosenfeld 2000, Giordano
and Avantagiatti 1999). In order to further characterise the role of CBP in the insulin
responsiveness of the glucagon promoter, and to localise any particular domain
required and/or sufficient to confer negative regulation by insulin, several constructs
were used where the GAL4 DNA-binding domain was fused with different parts of
CBP.
  As the first approach three constructs were used where the GAL4 DNA binding
domain was fused to N-terminal (amino acids 1-451), middle (amino acids 1061-
1891) and C-terminal (amino acids 1892-2441) part of CBP (Fig. 17 and 18).
Fig. 17. Schematic representation of the CBP protein. Main functional domains and
amino acids positions are indicated. C/H3: cystine/histidine-rich, HAT: histone
acetyltransferase, KIX: CREB-interacting domain, Q: glutamine-rich, cofactor-interacting




Fig. 18. Insulin inhibition of transcriptional activity conferred by the N- and C-terminal
parts of CBP. Expression vectors encoding GAL4-CBP fusion proteins (parts of CBP
depicted above the graph, see also Fig. 17) were transfected (2 µg/6-cm dish) into InR1-G9
cells together with -350(mutG1/G3)GluLuc reporter gene, and the cells were treated with
insulin (10 nM) or left untreated (control). Luciferase activity is expressed as percentage of
the mean value, in each experiment, of the activity of the GAL4-CBP (1-2441) without insulin.
Values are means ± SE of three independent experiments, each done in duplicate. C/H3:
cystine/histidine-rich, HAT: histone acetyltransferase, KIX: CREB-interacting domain, Q:
glutamine-rich, cofactor-interacting domain. A black diamond indicates a consensus PKB
phosphorylation site. *P<0.005 (Student’s t-test).
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When cotransfected together with the mutated glucagon reporter gene, in which both
Pax6 binding sites within G1 and G3 had been mutated into GAL4 binding sites (-
350(mutG1/G3)GluLuc), GAL4-CBP constructs containing N- and C-terminal parts of
CBP conferred strong basal transcriptional activity which was inhibited by insulin by
46% and 36% respectively (Fig. 18).  Similarly full length CBP conferred inhibition by
43%, which is consistent with previous findings (see above). In contrast construct
containing the middle part of CBP conferred relatively low transcriptional activity
which was not inhibited by insulin whatsoever (Fig. 18). The positive control (-
350GluLuc) was inhibited by insulin by 48%.
Mapping the insulin responsive domain within the C-terminal part of CBP.
Further mapping of insulin responsiveness was focused on the C-terminal part of
CBP, which was subject to several C-, N-terminal and internal deletions. These
deletion constructs were fused with the GAL4 DNA binding domain and cotransfected
with the doubly mutated glucagon reporter gene.
  The whole C-terminal part of CBP containing amino acids 1678 to 2441 conferred
basal transcriptional activity which was about 30% of the activity of the wild type
glucagon promoter and was inhibited by insulin by 42±3% (n=8). N-terminal deletions
(constructs 1880-2441 and 2040-2441) markedly raised the transriptional activity (16
and 10 –fold respectively), which was also inhibited by insulin (32±2% and 41±2%
respectively). Deleted regions contain the C/H3 domain and part of the HAT domain.
Further N-terminal deletion of amino acids 1678-2171 and 1678-2306  (constructs
2171-2441 and 2306-2441) resulted in a dramatic decrease of the transcriptional
activity and abolishment of the insulin inhibition.
  Noteworthy, the construct containing amino acids 2040-2170 (C-terminal deletion of
the region 2170-2441), conferred a transcriptional activity comparable to the whole
C-terminal part of CBP. This activity was inhibited by insulin by 49±3% (n=6), which
is also similar to the level observed for the whole C-termianl part  of CBP or the wild
type glucagon promoter. Interestingly, internal deletion of the region between amino
acids 2040-2170 (construct 1678-2441∆2040-2170) markedly reduced the transcriptional




Fig. 19. Mapping the insulin responsive domain within the C-terminal part of CBP.
Expression vectors encoding GAL4-CBP fusion proteins (2 µg/6-cm dish) were transfected
into InR1-G9 cells together with -350(mutG1/G3)GluLuc reporter gene. The GAL4-CBP
constructs are schematically depicted below the graph with indicated important functional
domains and amino acid positions. After transfection InR1-G9 cells were treated with insulin
(10 nM) or left untreated (control). Luciferase activity is expressed as percentage of the
mean value, in each experiment, of the activity of -350GluLuc (without insulin). Values are
means ± SE of three independent experiments, each done in duplicate. A black diamond
indicates a consensus PKB phosphorylation site. C/H3: cystine/histidine-rich, HAT: histone




Effect of overexpression of constitutively active protein kinase B (myrPKB) on the
activity of the glucagon promoter and activity conferred by CBP
To test whether PKB can regulate the CBP-mediated activity a constitutively active
form of PKB was overexpressed, myrPKB. The overexpression of myrPKB was
assumed to mimic the insulin effect.  In the myrPKB construct a myristolyation signal
is added which directs PKB to the plasma membrane where it is activated by
upstream kinases – PDK1 and PDK2 (Andjelkovic et al.1997).
Fig. 20. Inhibition of GAL4-CBP activity by myrPKB overexpression. Expression vectors
encoding GAL4-CBP fusion proteins (amino acid number indicated) were transfected (2µg/6-
cm dish) into InR1-G9 cells together with -350(mutG1/G3)GluLuc. When indicated also
constitutively active PKB expression vector (1µg/6-cm dish) - myrPKB was transfected. The
cells were treated with insulin (when indicated) (10 nM) or left untreated (control). Luciferase
activity is expressed as percentage of the mean value, in each experiment, of the activity of –
350GluLuc (without insulin and myrPKB). Values are means ± SE of three independent
experiments, each done in duplicate.
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  Together with the mutated glucagon reporter gene -350(mutG1/G3)Glu, constructs
were cotransfected where the GAL4 DNA binding domain was fused with full length
(1-2441), N-terminal (1-451) and smallest, insulin responsive, C-terminal part of CBP
(2040-2170) (Fig .20). As a control –350GluLuc was also transfected. The
overexpression of myrPKB inhibited transcriptional activity conferred by all three
GAL4-CBP constructs by 72±4% (n=6), 59±11% (n=6), and 77± 2% (n=6)
respectively (Fig. 20). Also the activity of the glucagon promoter was inhibited by the




  Insulin inhibits glucagon secretion and gene transcription. This important aspect of
body’s glucose homeostasis has a clinical significance in diabetes mellitus, which
apart from insulin deficiency, is characterised by high glucagon levels secondarily
contributing to hyperglycaemia (Unger and Orci 1981, Lefebvre 1995). However,
despite this clinical importance as a potential target for treating diabetes mellitus, the
molecular mechanism of inhibition of glucagon gene transcription by insulin is poorly
understood.
  It has been shown that 350 base pairs of the glucagon gene 5’-flanking region are
sufficient for negative regulation by insulin in the glucagon-producing pancreatic islet
cell line InR1-G9 (Philippe 1989). It was also hypothesised that the G3 element may
function as an insulin response element (IRE) of the glucagon gene. However, recent
deletional analysis of the –350 region (Grzeskowiak et al. 2000) failed to identify any
single element required and sufficient to confer the insulin responsiveness. On the
contrary it was speculated that the effect of  insulin depends rather on the presence
of both proximal promoter elements and more distal enhancer-like elements
(Grzeskowiak et al. 2000). The present study expands this hypothesis by showing a
critical role of the paired-domain transcription factor Pax6 in this interaction. It also
demonstrates that the Pax6-interacting coactivator CBP is capable to confer negative
regulation by insulin in glucagon promoter context-specific manner.
4.1 The involvement of Pax6 in the regulation of glucagon gene transcription
by insulin.
The results of the present study confirm the expression of Pax6 in adult pancreatic
islets (Turque et al. 1994, Sander et al. 1997). They also indicate that the transcripts
in the adult islets are fully consistent with the known Pax6 cDNA, with and without an
alternatively spliced exon 5a (Walther and Gruss 1994). One of the two Pax6 splice
variants expressed in mature pancreatic islets and islet cell lines (this study,
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Beimesche et al. 1999) binds through the PISCES motif to an enhancer-like element,
G3A, and, possibly together with cdx2/3 or brain-4 (Hussain et al. 1997, Jin and
Drucker 1996), to a proximal promoter element (G1) of the glucagon gene
(Beimesche et al. 1999, Knepel et al. 1990, Sander et al. 1997, Andersen et al. 1999,
Knepel et al. 1991, Ritz-Laser et al. 1999). The binding of Pax6 to both elements is
critical for basal activity and insulin responsiveness. The mere presence of a single
Pax6 binding site is not sufficient to confer the insulin response since reporter genes
containing the truncated glucagon promoter (-136GluLuc) or the 3’-deleted glucagon
promoter fragment from -350 to -150 include a Pax6 binding site but are not
negatively regulated by insulin (Grzeskowiak et al. 2000).
  However, Pax6 seems to play a critical role for the glucagon gene response to
insulin in pancreatic islet cell line InR1-G9. This glucagon-producing cell line shows
many characteristics of the mature A-cell and is regulated by insulin (Takaki et al.
1986) – it is therefore a useful model for studies of gene regulation by insulin.
This study provides evidence that Pax6 activity in InR1-G9 cells can be inhibited by
insulin. Firstly, the activity of an artificial minienhancer consisting of synergizing Pax6
binding sites (G3A) in front of a heterologous promoter (TK) was inhibited by insulin.
Secondly, insulin inhibited the GAL4-Pax6-mediated activity of the reporter gene
construct under control of multiple Gal4 sites and minimal E1B promoter. This effect
specifically depends on Pax6 because insulin had no effect on the transcriptional
activity conferred by the viral VP16 transcription factor; furthermore insulin did not
inhibit the expression of the GAL4-Pax6 fusion protein as revealed by electrophoretic
mobility shift assay and Western blotting. Thus, although the extent of inhibition of
GAL4-Pax6 transcriptional activity was less than that of –350GluLuc, these results
indicate that Pax6 is capable to confer insulin responsiveness in InR1-G9 cells.
  The present study also provides evidence that Pax6 is required for the repression of
the glucagon gene transcription by insulin. Coexpression of a portion of the Pax6
protein (amino acids 1 to 246) that contains the paired domain (without exon 5a) but
lacks the transactivation domain and most of the homeodomain,  dramatically
decreased basal activity and completely abolished insulin inhibition of the construct
driven by four copies of the Pax6-binding site, 4XG3A(T81)Luc. This suggests that
the expression of the Pax6 paired domain efficiently prevents Pax6 functions. The
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expression of the Pax6 paired domain also decreased basal transcription levels and
insulin inhibition of the glucagon gene (-350GluLuc), consistent with the assumption
that Pax6 is required for repression of glucagon gene transcription by insulin.
Furthermore, the overexpression of the Pax6 paired domain completely abolished the
inhibition of transcription by insulin of the G2 element in front of the truncated
glucagon promoter , G2(-136Glu), without altering its basal transcriptional activity.
This suggests that Pax6 binding to the proximal promoter element G1 is required for
insulin responsiveness conferred to the truncated promoter by G2.
  The requirement of Pax6 in the repression of the glucagon gene transcription by
insulin was also shown by the mutation of the Pax6 binding sites within G3, G1, and
G3 plus G1. In all three cases mutations decreased basal transcriptional activity and
markedly reduced inhibition by insulin of the glucagon promoter. Finally, when an
expression vector encoding a GAL4-Pax6 fusion protein was transfected together
with -350(mutG1/G3)GluLuc, basal transcriptional activity of the doubly mutated
glucagon promoter was raised to a level similar to that of the wild-type promoter.
Importantly, the activity mediated by the GAL4-Pax6 was inhibited by insulin to the
levels similar of the wild-type glucagon promoter. This effect of GAL4-Pax6 seems to
be specific and also not secondary to the restoration of the basal activity, because
the expression of GAL4-VP16 restored basal activity of the doubly mutated glucagon
promoter but did not confer insulin responsiveness. When taken together these
results suggest that Pax6 is not sufficient but required for insulin responsiveness of
the glucagon promoter.
4.2 Regulation of Pax6 activity by insulin-induced signalling pathways.
Pax6 confers insulin response to the glucagon promoter. Inspection of the Pax6
sequence revealed a putative protein kinase B (PKB) phosphorylation site in the C-
terminal part of the transactivation domain. It posed the possibility that Pax6 might be
directly regulated by the insulin signallig pathways – particularly by PKB. Few
examples exist of transcriptional factors which are regulated directly by insulin-
activated pathways as has been shown for FKHR (Tang et al. 1999, Rena et al.
1999) and AFX (Geert et al. 1999). In case of FKHR, which is implicated in the
transactivation of IGFBP-1 gene, insulin activates PKB which phosphorylates FKHR
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at three conserved sites. This phosphorylation promotes nuclear exclusion of FKHR
and thereby negatively regulates the FKHR-mediated transcription (Biggs et al.
1999). Negative regulation by PKB of FKHR-dependent genes involved in promoting
apoptosis has been shown as well (Tang et al. 1999). However, in InR1G9 cell line
Pax6 seems not to be directly affected by insulin-activated signalling pathways – and
particularly by PKB. Insulin-induced posttranslational modifications of a
transcriptional factor such as phosphorylation can affect DNA-binding pattern or
electro-phoretic mobility as has been shown for FKHR (Tang et al. 1999, Rena et al.
1999) or DAF-16 (Ogg et al. 1997). However, as revealed by EMSA using the
nuclear extracts from InR1-G9 cells, neither a change in the band pattern nor band
intensity was observed upon insulin treatment, which suggests that DNA-binding of
Pax6 is not affected by insulin-stimulated pathway(s). Furthermore, the insulin
treatment had also no effect on the expression level of Pax6 protein or its electro-
phoretic mobility properties as was revealed by Western blotting. These data are
consistent with the assumption that Pax6 protein level or posttranslational
modifications are not affected by the insulin treatment in InR1-G9 cells.
  Finally, these results are supported by an in vitro PKB assay. The
immunoprecipitated PKB from InR1-G9 cells treated with insulin did not
phosphorylate neither Pax6 paired domain, nor Pax6 full lenght protein (Barthel A.,
personal communication). This provides a direct evidence that, at least in vitro, Pax6
is not a direct substrate for PKB and might not be regulated by this kinase.
   It has been reported recently (Mikkola et al. 1999) that the transactivation domain
(TAD) of zebrafish Pax6 is phosphorylated in vitro at three sites by the mitogen-
acivated protein kinases (MAPKs): extracellular-signal regulated kinase (ERK) and
p38 kinase. One of three in vitro phosphorylation sites is strongly conserved in
evolution and is also phosphorylated in vivo which stimulates the transactivatory
properties of Pax6 TAD. However, the mutation of all three of these sites did not
affect the ability of insulin to inhibit Pax6 transcriptional activity in InR1-G9 cells.
These findings therefore do not support a role for these mitogen-activated protein
kinase phosphorylation sites in insulin action on the glucagon gene.
  The negative results presented above considering the regulation of Pax6 by PKB
and ERK/p38 do not exclude the possibility that Pax6 might be actually a target for
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these kinases in vivo. However, when taken together, this results do not provide an
evidence that Pax6, although crucial for the inhibition of glucagon gene transcription
by insulin, is directly targeted by insulin-stimulated signalling pathways in InR1-G9
cells.
4.3 Inhibition by insulin of the CBP-mediated transcriptional activity.
The C-terminal transactivation domain of Pax6 is proline/serine/threonine-rich and
can interact with the coactivator p300/CBP (Hussain and Habener 1999, Tang et al.
1998), suggesting that recruitment of CBP may be important for the distinct function
of Pax6 at the glucagon promoter. The present study shows that transcriptional
activity conferred by GAL4-CBP fusion protein to the doubly mutated glucagon
promoter was inhibited by insulin. In contrast, insulin did not affect GAL4-CBP activity
using a reporter gene with GAL4 binding sites in front of the minimal viral E1B
promoter, indicating that the specific glucagon promoter context is required for the
effect of insulin on CBP activity. If Pax6 functions through recruitment of CBP, the
fact that GAL4-Pax6 but not GAL4-CBP confers insulin responsiveness to the
5xGal4(E1B)Luc reporter gene may be explained by the assumption that CBP might
adopt a different conformation and may function differently when bound to the
promoter through recruitment by Pax6 or through fusion with the DNA-binding
domain of GAL4  (Hu et al. 1999). Different CBP conformation might also induce
interaction of CBP with different cofactors or/and general transcription factors
(Korzus et al. 1998, Kurokawa et al. 1998).
  CBP and the closely related protein p300 are modular proteins with multiple
functional domains (Eckner 1996, Korzus et al. 1998, Kurokawa et al. 1998, Torchia
et al. 1998). In addition to Pax6, other transcription factors that bind to the glucagon
gene 5’-flanking region can interact with CBP including Beta2/E47/E12 basic helix-
loop-helix proteins (Mutoh et al. 1998, Qiu et al. 1998), NFATp (Fürstenau et al.
1999, Garcia-Rodriguez and Rao 1998), Ets-like transcription factors (Fürstenau et
al. 1997, Yang et al. 1998), and CREB (Oetjen et al. 1994, Knepel et al. 1990, Kwok
et al. 1994) (Fig. 21). Interestingly, the functional domains of CBP are differentially
used by different transcription factors, implying conformational differences in the
CBP-based coactivator complex bound to different classes of transcription factors
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(Korzus et al. 1998, Kurokawa et al. 1998). Thus, through multiple contacts with CBP
or through recruiting other coactivators, the specific glucagon promoter context may
induce the formation of a promoter-specific nucleoprotein complex (Shikama et al.
1997). Pax6 and CBP may be essential components of such a complex, which
integrates the activities of proximal promoter elements and more distal enhancer-like
elements and the function of which is sensitive to insulin (this study, Grzeskowiak et
al. 2000).
4.4 Defining the insulin responsive region of CBP.
Pax6 directly interacts with CBP/p300 proteins (Hussain 1999, Tang 1998) and, as
shown in this work, CBP-mediated transcriptional activity is negatively regulated by
insulin in glucagon promoter context-specific manner. In the mapping of the CBP
protein performed in the present study the N-terminal and C-terminal parts
(aminoacids 1-451 and 1892-2441 respectively) conferred strong basal activity and
insulin responsiveness. Conversely, the middle part (aminoacids 1061-1891) was
rather a poor transactivator and its activity was not inhibited by insulin. These results
suggest that N- and C-terminal domains of CBP protein are sufficient to confer the
negative regulation by insulin. The molecular mechanism underlying inhibition by
insulin of the activity mediated by the N- and C-terminal parts of CBP can be
speculated to depend on the CBP-interacting cofactor/coactivator proteins.  The N-,
and C-terminal parts of CBP have been shown to interact with many cofactors
involved in the process of transactivation (Shikama et al. 1997). Many of them, like
p/CAF or p/CIP, are involved in a very precise and specific modulation of the CBP
activity and conferring signals from signalling cascades or transcriptional factors to
the general transcriptional machinery (Shikama et al. 1997, Perssi et al. 1999,
Martinez-Balbás et al. 1998, Hu et al. 1999). The N- and C-terminal parts might in
this view present an interacting platform for many cofactors which in turn allow the
insulin-induced cascade to affect the general transcriptional machinery.
  Inspection of the CBP sequence revealed a consensus phosphorylation site for
protein kinase B residing in the C-terminal part. Further mapping was therefore
focused on this region and C-terminal part of CBP was subject to several C-, N-
terminal and internal deletions. The transcriptional activity conferred by different parts
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was highly variable and might be explained by the modular constitution of CBP
(Eckner  1996, Korzus et al. 1998, Kurokawa et al. 1998, Torchia et al. 1998). In this
view the transcriptional activity of CBP would be a net output of inhibitory and
stimulatory activities of many subdomains. Furthermore, the degree of insulin
inhibition was highly correlated with the levels of transcriptional activity. Constructs
with low transcriptional activity were also least inhibited by insulin. In the present
study however, a single, smallest CBP region was mapped which is capable to
confer both transcriptional activity and high degree of insulin inhibition (49%). This
region resides between amino acids 2040 and 2170 and contains the p/CIP-
interacting domain. Furthermore, the internal deletion of this sequence (1678-
2441∆2040-2170) markedly reduced basal activity and insulin response. These results
provide an evidence that CBP region between amino acids 2040 and 2170 is
sufficient to confer the negative regulation by insulin. The fact that this domain of
CBP interacts with p/CIP poses an interesting speculation that actually this cofactor
might be affected by insulin-induced pathway and regulate transcription directly or by
modulating the activity of CBP. Recently p/CIP has been shown to regulate the CBP
function by modulating its acetyltransferase activity in a substrate selective fashion
(Perissi et al. 1999). Such effects were in turn speculated to be regulated by other
cellular factors or by postranslational modifications, which provides and example how
insulin-induced pathway might target p/CIP or/and CBP, and ultimately regulate
transcription.
  Interestingly, the mapping of the CBP C-terminal domain revealed that the
consensus PKB phosphorylation site is dispensable for the negative regulation by
insulin. This does not exclude the possibility that CBP might be phosphorylated in
vivo by PKB. Also CBP might be regulated by other kinase(s) along the insulin
signalling pathway(s) as has been shown for the regulation by calcium of activity
conferred by CBP mutant with deleted CAM kinase site (Hu et al. 1999).
4.5 Regulation of the CBP activity by PKB.
The role of  PKB in the regulation of the CBP-mediated transcriptional activity was
addressed by overexpression of a constitutively active form of PKB, the myrPKB.
Consistent with the previous findings, the activity conferred by the full length, N-
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terminal (1-451) and part of C-terminal domain (2040-2170) of CBP was inhibited by
insulin treatment. Noteworthy, a similar or even stronger inhibition effect was
observed when the myrPKB was overexpressed. The overexpression of the myrPKB
also inhibited the –350GluLuc activity which agrees with previous observations
(Dellas C, personal communication). These results suggest that PKB can regulate
the CBP-mediated activity and can mimic the negative regulation of the glucagon
gene transcription by insulin.
  The subdomains of CBP which activity is inhibited by overexpression of the myrPKB
do not contain the consensus PKB phosphorylation site. Although this does not
exclude the possibility that these domains might still be phosphorylated by PKB in
vivo, it might suggest that a direct target for the insulin action is in fact a cofactor(s) of
CBP or synergizing interaction between CBP and cofactors rather than the CBP
molecule itself.
4.6 Final concept: Inhibition of glucagon gene transcription by insulin through
IRE-binding factor(IRF)-independent mechanism.
  Recently a novel and an interesting model has been proposed in which insulin
inhibits gene transcription through an IRE-independent mechanism (Leahy 1999,
Pierreux et al. 1998, Pierreux et al. 1999, Yeagley et al. 1998). In glucocorticoid-
induced 6-phosphofructo-2-kinase (PFK-2) gene transcription (Pierreux et al. 1998,
Pierreux et al. 1999) and in cAMP-induced PEPCK gene transcription (Yeagley et al.
1998) it has been shown that in each case a combination of several DNA elements
and interacting transcription factors, called glucocorticoid or cAMP response unit,
respectively, are required for both full responsiveness to the respective stimulus and
inhibiton by insulin. Site-directed mutational analysis revealed that none of the factors
seems to be individually involved in the inhibitory effect of insulin (Pierreux et al.
1998, Pierreux et al. 1999, Yeagley et al. 1998). This led to the conclusion that the
unique array of factors may be recognized, or stabilized, by a specific coactivator
complex and that inhibition of gene transcription by insulin may result from the
disruption of this higher order complex (Pierreux et al. 1998, Pierreux et al. 1999,
Yeagley et al. 1998).
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  Evidence suggests that CBP is part of this complex on the PEPCK promoter (Leahy
et al. 1999, Pierreux et al. 1998, Pierreux et al. 1999, Yeagley et al. 1998) and this
might also hold true for PFK-2 (Pierreux et al. 1999). The finding that the mitogen-
regulated S6 kinase pp90RSK binds to the C/H3 region of CBP and regulates CBP
function (Nakajima et al. 1996) gives an example how an intermediate in a signaling
cascade is able to interact with CBP and control gene transcription.
  The results of the present study support this concept. Insulin responsiveness of the
glucagon promoter was suggested to be dependent on the synergistic interaction
between proximal promoter and more distal enhancer-like elements (Grzeskowiak et
al. 2000). Pax6 binding to both promoter (G1) and enhancer (G3) elements presents
a crucial integrating factor and is required for the insulin responsiveness.
Fig. 21. The importance of Pax6 and CBP in the insulin responsiveness of the
glucagon promoter. Schematically presented are regulatory elements of the glucagon
promoter and their transcriptional factors. The transcription factors which were reported to
interact with CBP are enlarged (CREB, ETS/NFATp, E12/Beta2). Pax6 is shown to bind to
PISCES within G1 and G3 elements and interact with CBP which in turn is a part of the large
nucleoprotein complex. Insulin stimulus disrupts interaction between the holoenzyme and the
nucleoprotein complex which inhibits transactivation of the glucagon gene transcription.
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Pax6 interacts with the coactivator protein CBP, activity of which has been also
shown in this study to be regulated by insulin. CBP is a well established integrator of
signals coming from transcriptional factors and intracellular signalling pathways to the
general transriptional machinery and chromatin (Shikama et al. 1997). Furthermore,
the CBP-mediated activity can be further modulated by interaction with CBP-specific
cofactors, like p/CIP or p/CAF (Shikama et al. 1997, Perssi et al. 1999). It is therefore
tempting to speculate that within the specific context of the glucagon promoter a
nucleoprotein complex is being induced. Critical role in establishing this complex
might play the interaction of Pax6 with the CBP/p300 coactivator (Fig. 21). In this
view insulin might target this large, glucagon promoter-specific protein complex
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